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1 Summary 
 
 Formation of metastases in the lungs is the major cause of death in patients suffering 
from osteosarcoma (OS), the most common primary bone cancer in children and adolescents. 
Significant clinical improvements over the past several decades through the use of 
combination chemotherapy and surgery have led to a dramatic increase in the survival of 
patients with localized disease. However, patients with metastatic or recurrent disease 
continue to have a very poor prognosis, with <20% long term survival. The failure of 
treatment in these patients is often associated with gained resistance of tumor cells to 
chemotherapy. Therefore, it is of substantial relevance to identify molecular markers 
associated with the increased metastatic potential or chemoresistance, which may serve as 
diagnostic or prognostic factors. Acquiring insight into the basic biology of OS progression 
will make the identification of such new therapeutic targets possible with the final goal to 
develop treatment strategies that eradicate metastases and thereby improve the survival of OS 
patients. 
 Metastasis is a complex multistep process which involves detachment of tumor cells 
from primary tumor mass, invasion of local stroma, intravasation, survival during transport in 
the circulation, arrest at distant organ sites, extravasation into corresponding parenchyma, 
adaptation to this new foreign tissue microenvironment and finally colonization in the distant 
organ. CD44 has been linked with increased metastatic spread in various types of cancer, 
however, its function in sarcomas has been only superficially addressed. CD44 and its 
numerous splice variants constitute a family of widely distributed type I transmembrane 
glycoproteins that serve as cell-cell and cell-matrix adhesion molecules and as principal 
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receptors for hyaluronan (HA), a major component of the extracellular matrix in many tissues 
including bone.  
 In this thesis, the prognostic value of CD44 expression for OS patients’ outcome and the 
biological relevance of CD44/HA interactions for in vitro malignant properties of OS tumor 
cells and for in vivo OS progression and metastasis in orthotopic xenograft OS mouse models 
were investigated.  
Our tissue microarray analysis of OS tumor specimens identified CD44 expression as an 
additional indicator of poor prognosis together with metastasis and resistance to 
chemotherapy, the two best established predictors of poor OS patient’s outcome.  
In vitro, CD44 expression correlated with the adhesion to HA and with cell migration. 
Moreover, cells with forced CD44 expression were more resistant to cisplatin. 
In vivo, our studies in different human xenograft OS mouse models revealed that CD44 
gene products may play a dual role in regulating OS progression and metastases, depending 
on the cellular background. However, in the context of osteoblastic OS, the most common 
type of OS, our study demonstrated for the first time that CD44 promotes OS growth and 
dissemination in a HA-dependent manner and that CD44 expression is associated with in vitro 
enhanced migration rates and chemoresistance to cisplatin. This is also consistent with 
patient’s outcome as observed with tissue microarray analysis. On the other hand, in a 
subgroup of OS, where Ras signaling is increased, CD44 may act as a tumor suppressor 
probably by upregulation of merlin.  
Taken together, the findings presented in this thesis underscore the important role of 
CD44s/HA interaction in determining tumor malignancy in experimental OS. In conclusion, 
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our results highlight CD44/HA interaction as a promising target for therapeutic intervention in 
this highly aggressive cancer type. 
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2 Zusammenfassung 
Das Osteosarkom (OS) ist ein aggressiver Knochentumor, der vor allem bei Kindern 
und Heranwachsenden auftritt. Im Falle eines lokal begrenzten Tumors haben verbesserte 
Operationstechniken und chemotherapeutische Behandlung in den letzten paar Jahrzenten zu 
einem Anstieg der Lebenserwartung der betroffenen Patienten geführt. Bei Patienten, die 
bereits Metastasen vorweisen, vorwiegend in der Lunge und am Skelett, bleibt die 
Lebenserwartung weiterhin tief und liegt bei <20%. Um die Lebenserwartung auch bei diesen 
Patienten anheben zu können, ist es daher wichtig, Einblick zu gewinnen in die molekularen 
Veränderungen, die zu einem erhöhten Metastasierungspotential und/oder zur Bildung einer 
Resistenz gegen die Chemotherapeutika führen. Mit der Identifizierung solcher molekularen 
Komponenten sollte es möglich sein, eine Voraussage machen zu können, welche Patienten 
einem besonders hohen Risiko ausgesetzt sind und dann für diese Patienten gezielte 
Therapien zu entwickeln. 
Eine Krebszelle muss viele Hindernisse überwinden, um an einem vom Tumor 
entfernten Ort eine Metastase bilden zu können. Zuerst muss sie sich von der Tumormasse 
ablösen, dann durch das den Tumor umgebende Gewebe wandern und in ein Lymph- oder 
Blutgefäss eindringen. Dort muss die Zelle überleben bis sie sich in den Gefässen des 
Zielorgans anheften muss, um diese wiederum penetrieren zu können. Im Zielorgan 
angekommen, muss sich die Zelle an die neue Umgebung anpassen und fort geeignete 
Bedingungen schaffen, um letztendlich erfolgreich das Zielorgan besiedeln zu können. Bei 
andern Tumorarten als dem OS konnte gezeigt werden, dass einige dieser kritischen Schritte 
durch das Zelloberflächenprotein CD44 begünstigt werden. CD44 kann Gewebe spezifisch in 
verschieden langen Formen gebildet werden und dient der Zell-Zell und Zell-Matrix 
Interaktion. Im Knochen ist ein Hauptbestandteil der extrazellulären Matrix das Hyaluronan 
(HA), an das die Zellen durch den CD44 Zelloberflächenrezeptor binden können. 
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In der vorliegenden Arbeit habe ich folgende Aspekte untersucht: 1) Korreliert die 
CD44 Expression in Gewebeproben von OS Patienten mit deren Ueberlebensrate? 2) Hat die 
Manipulation der CD44 Expression in OS Zellen einen Einfluss auf deren in vitro 
Eigenschaften? 3) Welchen Einfluss hat die CD44 Expression auf das 
Metastasierungspotential von OS Zellen nach Transplantation in den Knochen von Mäusen in 
vivo.  
Die Expressionsanalyse der OS Gewebeproben zeigte, dass die Ueberlebensrate von 
Patienten mit Metastasen oder Chemotherapieresistenz zusätzlich erniedrigt ist, wenn die 
CD44 Expression hoch ist. Als Folge sind diese Patienten mit hoher CD44 Expression einem 
besonders hohen Risiko ausgesetzt. 
In vitro konnte eine positive Korrelation der CD44 Expression mit der Bindung an HA 
und mit der Migrationsrate der Zellen gezeigt werden. OS Zellen mit erhöhter CD44 
Expression waren zudem weniger empfindlich gegenüber Zytostatika. 
In vivo konnte gezeigt werden, dass CD44 in osteoblastischen OS Zellen, dem 
häufigsten OS Typ, beiträgt zu einem vermehrten Tumorwachstum und zu einem erhöhten 
Metastasierungspotential, was zur in vitro beobachteten erhöhten Zellmigrationsrate und 
Chemoresistenz und zur erniedrigten Ueberlebensrate der Patienten mit erhöhter CD44 
Expression passt. In einer Untergruppe von OS allerdings, die eine erhöhte Ras Aktivierung 
aufweist, scheint CD44 die Tumorbildung und die Metastasierung zu unterdrücken, indem es 
die Expression des Tumorsuppressors Merlin kontrolliert. CD44 kann dementsprechend Zell 
spezifisch unterschiedliche Wirkung haben auf die OS Entwicklung. 
Die Resultate dieser Studie weisen auf eine wichtige Rolle von CD44 und der 
Interaktion mit HA bei der Tumorbildung und der Metastasierung beim OS hin. Abhängig 
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vom Tumortyp können CD44 und/oder HA als therapeutische Ziele ins Auge gefasst werden, 
um diesen aggressiven Tumor besser behandeln zu können. 
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3 Introduction 
3.1 Osteosarcoma 
3.1.1 Definition and epidemiology 
Osteosarcoma (OS) is the most common primary tumor of bone in children and 
adolescents, which is characterized by the presence of malignant spindle cells that produce 
osteoid and/or immature bone (Picci, 2007). The incidence of OS in the human population is 3 
cases per million per year, but amounts to 8-11 cases/million/year in adolescents of between 
15 and 19 years of age (Ritter and Bielack, 2010). OS is a disease with bimodal age 
distribution, with the first peak during the second decade of life, throughout the growth spurt, 
and the second peak in the elderly adults (Marina et al., 2004). Males are affected more 
frequently than females (Stiller et al., 2001). 
3.1.2 Etiology 
The etiology and pathogenesis of OS remains obscure. The only proven exogenous 
risk factor for developing OS in humans is exposure to ionizing radiation, which accounts for 
in only 2% of osteosarcomas. Since a long interval of 10-20 years between radiation exposure 
and OS formation has been observed, radiation-induced OS is typically observed in adults and 
is not thought to play a major role in pediatric disease. The majority of osteosarcomas are 
sporadic. However, a number of inherited genetic predispositions have been reported to be 
associated with OS, which include hereditary retinoblastoma (Rb gene mutation), Li-
Fraumeni (p53 mutation), Bloom (BML mutation), Rothmund-Thomson (RECQL4 mutation) 
and Werner (RECQL2 mutation) syndromes and Paget’s disease (SQSTM1 mutation) 
(reviewed in (Clark et al., 2008; Fuchs and Pritchard, 2002; Wang, 2005).    
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3.1.3 Cytogenetic and molecular aberrations in OS 
Disease-specific chromosomal translocations are characteristic for several sarcomas, 
such as Ewing’s sarcoma and alveolar rhabdomyosarcoma. In contrast, osteosarcomas do not 
display such specific genetic alterations, but they have a very complex karyotype, with 
numerical and structural chromosomal abnormalities with considerable heterogeneity (Bridge 
et al., 1997; Helman and Meltzer, 2003). 
3.1.4 Clinical characteristics and diagnostics 
The typical symptoms of OS are local pain, followed by soft tissue swelling, which 
usually arise after trauma or vigorous physical training (Marina et al., 2004). In rare cases, 
patients present with pathological fractures. Although OS can occur in any bone, it is mainly 
observed in the metaphysis of long bones. The most common primary sites are the distal 
femur (40%), the proximal tibia (20%) and the proximal humerus (10%), with approximately 
50% of the cases occurring around the knee (Longhi et al., 2006). OS rarely develops in the 
axial skeleton (<10% of patients in the pediatric age), where it mainly affects the pelvis 
(Ritter and Bielack, 2010). 
At the time of diagnosis, between 15 and 20% of the patients present with detectable 
metastases. However, 80% of the patients with localized disease develop metastases after 
surgical resection. The metastases are commonly found in the lungs and less frequently in the 
bone. The major cause of death in OS patients are pulmonary metastases with respiratory 
failure due to widespread disease (Marina et al., 2004). 
Clinical examinations for the diagnosis of OS comprises full patient history, physical 
examination, plain radiography, magnetic resonance imaging (MRI), computed tomography 
(CT), dynamic bone scintigraphy and biopsy. Plain radiography of bone affected by OS shows 
characteristic osteoblastic, osteolytic or mixed lesions. Ossifications in the soft tissue often 
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appears as a radial, so called “sunburst” pattern. Codman’s triangle is a specific feature seen 
in radiographs that results from periostal new bone formation and lifting of the cortex (Figure 
1).  
 
  
 
 
 
A           B                 C     D 
Figure 1: Typical radiographic appearance of OS. Anteroposterior (A) and lateral (B) radiograph of 
the left distal femur show a typical “Codman`s triangle” (arrow) in an OS patient. A “sunburst”-type periostal 
reaction (arrows) can be seen in the anteroposterior (C) and lateral (D) radiograph of the right distal femur of an 
OS patient.  
CT and MRI are used to assess the extensions of the tumor and the involvement of 
surrounding structures such as vessels, nerves and soft tissue (Aisen et al., 1986). Chest CT 
and isotope scans with technetium or thallium are applied in order to visualize lung and bone 
metastases (Figure 2) (Wittig et al., 2002).   
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Figure 2: CT and scintigraphic imaging of OS. (A) Chest CT scan indicating a large lung metastasis 
(arrow). (B) Bone scintigraphy corresponding to the X-ray shown in Figure 1c, d. High uptake of 
99m
Tc in the 
right distal femur (arrow). High uptake in the bladder, kidney, heart and brain are regular findings. 
 
Diagnostic histology of primary tumor biopsy tissue is mandatory to confirm the 
radiological findings. OS has a wide spectrum of histological appearances, but the hallmark is 
the presence of osteoid or immature bone produced by malignant mesenchymal tumor cells 
(Longhi et al., 2006). Three major subtypes of conventional OS are recognized by the World 
Health Organization (WHO): osteoblastic, chondroblastic and fibroblastic OS, classified 
based on the predominant type of matrix within the primary tumor. Additional histologic 
variants include teleangiectatic, small cell, parosteal, periosteal, low grade central and high 
grade surface OS (Marina et al., 2004).  
The most widely used staging system, the Enneking system, combines histologic 
grading (low grade: stage I; high grade: stage II) and anatomical tumor extension (A: 
intracompartmental; B: extracompartmental). Patients with distant metastases are categorized 
as stage III. The vast majority of cases are stage IIB at presentation (Enneking et al., 1980). 
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3.1.5 Treatment 
 
Current state-of-the-art treatment of OS patients requires a multidisciplinary approach 
and includes neoadjuvant (preoperative) multi-agent chemotherapy, followed by resection of 
the primary tumor and subsequent adjuvant (postoperative) chemotherapy (Ta et al., 2009). 
Complete surgical resection of the primary tumor is fundamental for OS cure. Traditionally, 
amputation was the sole treatment, however, advances in surgical techniques enabled the 
limb-sparing procedures, which are nowadays safely performed in 90%-95% of the patients 
(Wittig et al., 2002). Neoadjuvant and adjuvant therapies, introduced in the late 1970’s with 
the goal to destroy tumor cells, to decrease the tumor burden and to eradicate 
micrometastases, resulted in a significant increase in the 5-year disease-free survival to up to 
70% (Bacci et al., 2002; Campanacci et al., 1981; de Kraker and Voute, 1989; Enneking, 
1979; Rosen et al., 1982; Rosenburg et al., 1979). Doxorubicin, cisplatin, ifosfamide and 
high-dose methotrexate have been shown to be most effective in OS treatment. However, 
polychemotherapy may be associated with severe toxicities, such as permanent damage of 
cardiac (Lipshultz et al., 1995), renal (Rossi et al., 1994), auditory and reproductive function 
and other late effects including secondary malignancies (Aung et al., 2002). The mechanisms 
of action and major side effects of current chemotherapeutics used are listed in Table 1.  
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Agent Mechanism of action Side effects 
Doxorubicin (Adriamycin) 
Inhibition of DNA and RNA 
synthesis by intercalating at 
points of local uncoiling of 
the DNA double helix. 
Cardiomyopathy, transient 
electrocardiographic 
abnormalities, 
emesis, alopecia, mucositis, 
myelosuppression 
Cisplatin (Platinol) 
Inhibition of DNA synthesis 
through the formation of 
DNA cross-links 
Acute or chronic renal 
failure, peripheral 
neuropathy, ototoxicity, 
emesis, myelosupression, 
alopecia, hypomagnesemia 
Ifosfamide Inhibition of DNA synthesis 
by crosslinking DNA strands 
Hemorrhagic cystitis, renal 
failure, myelosuppression, 
alopecia, emesis, 
encephalopathy 
Methotrexate 
It is a antifolate,, and inhibits 
synthesis of purine and 
thymidine  by binding to 
dihydrofolate reductase 
Renal failure, mucositis, mild 
myelosuppression, rarely, 
central nervous system 
effects 
Table 1. Chemotherapeutic agents for the treatment of OS 
 
The assessment of tumor necrosis following preoperative therapy has been proven to 
be a reliable prognostic factor and it correlates with disease-free and overall survival (Bielack 
et al., 2002; Glasser et al., 1992). The degree of necrosis is evaluated according to the Huvos 
grading system (Huvos, 1981)(Bielack, Kempf-Bielack et al. 2002). The patients are 
classified as poor responders if they show <90% of necrosis (Grade I: no necrosis, Grade II: 
50%-90% of necrosis), whereas good responders correspond to Grade III (necrosis between 
90% and 100%) and Grade IV (total necrosis) (Bielack et al., 2002) . The histological 
response to neoadjuvant therapy correlates significantly with prognosis and allows tailoring of 
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the postoperative treatment according to different risk groups. Currently, a randomized trial of 
the EURAMOS (European and American Osteosarcoma; Figure 3) study group aims at 
optimizing the treatment modality for individual patients based on response to preoperative 
chemotherapy (Bielack et al., 2008; Carrle and Bielack, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: EURAMOS 1 treatment outline. OS patients receive 2 cycles of neoadjuvant chemotherapy 
with doxorubicin, cisplatin and methotrexate followed by surgery. Subsequently they are divided into 2 groups 
distinguishing poor responders from good responders according to Huvos’ classification. Good responders are 
randomly subdivided into 2 groups, with 1 group additionally receiving interferon-alpha as maintenance therapy 
after 4 cycles of adjuvant chemotherapy. Poor responders are also randomly subdivided in 2 groups to evaluate 
the benefit of etoposide/ifosfamide amendment. M = high-dose MTX, A = adriamycin (doxorubicin), P = 
Cisplatin, ifn = pegylated interferon alpha maintenance, I = high-dose ifosfamide, E = etoposide (Adapted from 
(Bielack et al., 2008)). 
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These significant clinical improvements over the past several decades through the use 
of combined chemotherapy and surgery have led to a dramatic increase in the survival of 
patients with localized disease. However, patients with metastatic or recurrent disease 
continue to have a poor prognosis, with <20% long term survival (Marina et al., 2004). 
Therefore, it is of great importance to elucidate the molecular mechanisms leading to 
increased metastatic potential. Recently, a number of emerging molecular markers have been 
shown to play an important role in OS metastasis. The identified genes are mostly involved in 
cell adhesion, migration and angiogenesis. Some examples that have been correlated to 
prognosis are ezrin, MMP-2, MMP-9, CXCR4/SDF1, uPA/uPAR and survivin. Several of 
them are already being tested as potential therapy targets in preclinical trials (reviewed in 
(Clark et al., 2008; Wang, 2005)).    
In conclusion, a better understanding of the basic biology of OS progression will 
enable us to devise novel strategies aiming at suppression of metastasis, the major cause of 
death in OS, and to finally improve the survival of these patients.  
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3.2 Metastasis 
One of the hallmarks of malignant tumors is their ability to metastasize and >90% of 
deaths in cancer patients is attributable to metastatic disease. Metastases remain the main 
barrier to successful cancer management because of their systemic nature and resistance to 
conventional therapies. The gain of metastatic ability of most cancers leads to clinically 
incurable disease. Metastasis is a complex multistep process, often referred to as “invasion-
metastasis cascade”, which involves spread of cancer cells from their primary site and 
establishment of new colonies in anatomically distant organs (Valastyan and Weinberg, 
2011).  
The metastatic process includes detachment of tumor cells from primary tumor mass, 
invasion of local stroma, intravasation (penetration of local blood and/or lymphatic vessels), 
survival during transport in the circulation, arrest at distant organ sites, extravasation into 
corresponding parenchyma, adaptation to this new foreign tissue microenvironment and 
finally reinitiation of proliferation of micrometastatic lesions and generation of macroscopic 
metastases, defined as colonization. In order to give rise to a metastatic tumor, a tumor cell 
needs to go through all these processes successfully. Particular stages, such as colonization, 
are highly inefficient and, consequently, rate limiting (Figure 4). Efficient steps in the 
metastatic cascade, on the other hand, include survival in the circulation, arrest at distant sites 
and extravasation. Experimentally it was shown that a tiny proportion (<0.02%) of 
intravenously injected cells generate macroscopic metastases (Luzzi et al., 1998). The final 
outcome of the metastatic process – the formation of clinically relevant lesions - is governed 
both by the intrinsic properties of cancer cells and their multiple and complex interplay with 
host components (Chambers et al., 2002; Fidler, 2003; Langley and Fidler, 2007). 
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Figure 4: The invasion-metastatasis cascade. The metastatic process is depicted as a sequence of 
interlinked, distinct steps. Tumor cells escape the primary tumor site through local invasion of surrounding 
stroma, migration and intravasation of lymphatic and/or blood vessels. Once in the circulation, cancer cells must 
avoid the immune attack and survive the transport until they are trapped in capillary beds of a distant organ. The 
arrest of circulating tumor cells at a specific site may occur by mechanical entrapment due to size restriction and 
by specific adhesive interactions. Following extravasation, tumor cells must adapt to the foreign milieu. Some 
micrometastases will eventually acquire the ability to reinitiate growth and form macroscopic metastases. The 
last step in the cascade – colonization - is the most inefficient of all. (Adapted from (Langley and Fidler, 2007)). 
 
3.2.1 Organ-specific metastasis 
Clinical observation of cancer patients revealed that certain tumor types have a 
propensity to metastasize to preferred distant organs (Figure 5). For instance, breast cancer 
usually spreads to bone, liver, brain and lungs, whereas prostate cancer metastasizes 
preferentially to bone. Metastases of colorectal cancer occur most prominently in the liver. 
Pulmonary metastases frequently develop in patients suffering from osteosarcoma. 
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Figure 5: Characteristic sites of metastatic spread for solid tumors.  
(Adapted from (Chiang and Massague, 2008)). 
 
In 1889, Stephen Paget published the “seed and soil” hypothesis of metastatic 
outgrowth, whereby he explained the non-random pattern of metastatic colonization, 
proposing that metastasis depends on the cross-talk between cancer cells (“seed)” and the 
microenvironment within specific distant organs (“soil”) (Paget, 1989). In 1928, James Ewing 
challenged Paget’s theory, claiming that anatomical arrangement of the vascular system 
determines the organ-specific metastasis (Ewing, 1928). The “seed and soil” theory was 
revived when studies by Isaiah Josh Fidler demonstrated that, although the cancer cells 
reached the vasculature of all organs, metastatic lesions selectively developed in certain 
organs, but not others (Fidler, 2003; Fidler and Kripke, 1977; Hart and Fidler, 1980; Psaila 
and Lyden, 2009). Eventually, both concepts revealed the proposal that the dissemination of 
tumor cells is affected by circulatory routes, but in fact the outgrowth of macrometastasis 
depends on the seeding of compatible tissues.  
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The tissue tropism of metastasizing cells to specific sites can be explained by several 
mechanisms: chemokine-receptor mediated chemotaxis, the establishment of a metastatic 
niche, and a genetic program within tumor cells that enables them to adapt to a particular 
microenvironment (Bacac and Stamenkovic, 2008).  
The first mechanism involves chemokines and their receptors. Target organs release 
chemoattractants that actively guide tumor cells expressing “matching” chemokine receptors 
to specific destinations from the circulation (Joyce and Pollard, 2009; Muller et al., 2001; 
Zlotnik, 2004). For example, breast cancer cell express high levels of CXCR4 and CCR7. 
Signaling through these chemokine receptors mediates actin polymerization and pseudopodia 
formation that contributes to a chemotactic and invasive response. The homing is achieved 
through respective cognate ligands CXCL12 and CCL21, which are expressed in lymph 
nodes, lung, liver and bone marrow tissue - sites to which breast tumors commonly 
metastasize - but not in other organs. Moreover, blocking of either CXCL12 or CXCR4 
inhibits metastasis of breast cancer cells in animal models (Muller et al., 2001). The 
involvement of the CXCL12/CXCR4 axis has also been implicated in OS metastasis 
progression (Perissinotto et al., 2005).  
The metastatic niche model proposes that primary tumors produce factors that 
orchestrate the preparation of the local parenchyma in distant organs prior to the seeding of 
metastatic cells. Cancer cells and their associated stromal cells secrete an array of chemokines 
that recruit bone-marrow derived endothelial and hematopoietic progenitor cells to relevant 
organs prior to tumor cell arrival. These cells expressing VEGFR1 were suggested to alter the 
microenvironment, which further promotes homing and engraftment of circulating tumor cells 
in these specific destination sites (Kaplan et al., 2006; Kaplan et al., 2005). 
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Gene expression profiling of breast cancer primary tumor tissue revealed a “metastasis 
signature” that predicts onset of metastasis and correlates with poor prognosis of the patients 
(Ramaswamy et al., 2003; van 't Veer et al., 2002). It has also been implied that a set of genes 
may regulate organ specific metastatic dissemination. Minn et al. identified a set of genes 
responsible for the lung tropism of the human MDA-MB231 breast carcinoma cell line (Minn 
et al., 2005). The same cell line has been used to identify genes that mediate breast cancer 
metastasis to bone (Kang et al., 2003).  
3.2.2 Metastasis genes 
Three classes of genes controlling the biological processes during the metastatic 
cascade have been defined: 
 metastasis initiation genes 
 metastasis progression genes 
 metastasis virulence genes (Nguyen et al., 2009).  
Metastasis initiation genes promote cell motility, epithelial-mesenchymal transition 
(EMT), degradation of the extracellular matrix (ECM), invasion, recruitment of bone marrow 
progenitors, angiogenesis or evasion of the immune system. For example, EMT programs are 
orchestrated by a set of pleiotropically acting transcription factors, such as TWIST1, SNAI1 
and SLUG (Yang and Weinberg, 2008). Invasion is supported by metadherin in breast cancer 
(Hu et al., 2009) and by the metastasis-associated in colon cancer 1 (MACC1) gene in 
colorectal carcinoma (Stein et al., 2009).  
Metastasis progression genes can provide both local advantage in the primary tumor 
and distal advantage in the metastatic microenvironment. These genes regulate extravasation, 
survival in the circulation and re-initiation of proliferation at the distal site. MMP1, MMP2, 
EREG, ANGPTL4, COX2 belong to this group of genes and were shown to enhance the 
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extravasation of breast cancer cells in the lungs, by disrupting cell-cell junctions between 
pulmonary vascular endothelial cells (Gupta et al., 2007; Padua et al., 2008). 
Metastasis virulence genes, however, don’t participate in primary tumor development, 
but are essential for organ-specific metastatic colonization, the final step of the invasion-
metastatic cascade. Examples of this group of genes are interleukin 11 (IL11) and parathyroid 
hormone-related protein (PTHRP), which facilitate the formation of osteolytic metastasis in 
the bone by breast tumor cells, but do not provide advantage in primary tumors (Mundy, 
2002; Yin et al., 1999). 
3.2.3 Adhesion-molecular effector mechanism of metastasis 
 The relevance of cell-cell and cell-matrix adhesion and their involvement in all the 
subsequent phases of the metastatic journey has been well established. In addition to 
proteolysis, adhesion is considered a fundamental molecular effector mechanism employed by 
a metastatic cell (Bacac and Stamenkovic, 2008). 
Adhesion molecules can modulate metastasis both in a positive and a negative manner. 
Detachment of cancer cells from the primary tumor mass and infiltration of adjacent tissue is 
supported by loss of intercellular contacts through downregulation of cell surface adhesion 
molecules. Continued changes in the adhesive properties of tumor cells facilitate their 
locomotion on vessel endothelium and trans-endothelial migration, survival in the blood or 
lymphatic stream, movement through host parenchymal tissues and finally restart of growth at 
secondary sites.  
In conclusion, successful execution of metastatic dissemination requires tumor cells to 
display major phenotypic plasticity, which enables them to appropriately interact with 
surrounding cells and matrix elements at each stage of the metastatic process. Adaptation of a 
cells’ adhesion profile is substantially dependent on the activity of different classes of cell 
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adhesion molecules, such as cadherins, integrins, members of the immunoglobulin 
superfamily and CD44 (Balzer and Konstantopoulos, 2011).  
3.3 CD44 
The CD44 protein family consisits of widely expressed type I transmembrane 
glycoproteins with a large repertoire of biological functions in both health and disease. They 
participate in various physiological and pathological processes including development, wound 
healing, inflammation, hematopoiesis, immune response and tumor progression. CD44 
molecules are the principal receptors for hyaluronan (HA), a major component of the 
extracellular matrix also in bone (Aruffo et al., 1990). The functional diversity is due to the 
structural heterogeneity of CD44 glycoproteins, resulting from alternative splicing of initial 
gene transcripts and post-translational modification of the proteins. CD44 glycoproteins can 
vary in molecular weight from 80 to 200 kDa (Herrlich et al., 1998; Naor et al., 1997; Ponta et 
al., 2003). 
3.3.1 CD44 gene and protein structure 
All CD44 isoforms are encoded by a single gene, located in humans on chromosome 
11 (Goodfellow et al., 1982) and in mice on chromosome 2 (Colombatti et al., 1982). The 
gene consists of 20 exons, 10 of which can be subject to alternative splicing (variant v1-v10 
exons) (Figure 6) (Screaton et al., 1992). Theoretically, multiple combinations of variant 
exons could give rise to more than 1000 different isoforms. Tissue-specific splicing results in 
the formation of the standard CD44 isoform (CD44s), lacking all variant exons, in cells of 
mesenchymal origin (Figure 6). It is ubiquitously expressed and located in the membrane of 
most vertebrate cells during fetal development and in adult organisms. The variant isoforms, 
named by the exons they contain, are expressed in only few epithelial tissues, mainly in 
proliferating cells, during embryonic development and in several cancers (Naor et al., 1997). 
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Some differentiated ectodermal cells, on the other hand, express an isoform that contains all 
the protein domains encoded by the variant exons (Hudson et al., 1995; Sherman et al., 1998). 
Interestingly, alternative splicing is also controlled by mitogenic signals, such as the 
stimulation of the Ras-Mek-Erk pathway (reviewed in (Marhaba and Zoller, 2004)).  
All CD44 proteins structurally comprise a large extracellular domain, a 
transmembrane region and an intracellular cytoplasmic tail (Figure 7). The extracellular 
region includes an amino-terminal globular domain, encoded by exons 1 to 5, and the 
membrane-proximal stem structure (stalk region), encoded by the exons 16 and 17. The 
variant exon products can be incorporated in this stem structure. Exon 18 encodes the 
transmembrane domain, whereas the intracellular cytoplasmic region is encoded by the exons 
19 and 20. A very rarely expressed short version of CD44 contains a cytoplasmatic tail of 
only 3 amino acids (Goldstein and Butcher, 1990). 
 
Figure 6: CD44 gene structure. (A) CD44 exon map. Green bars represent exons encoding constant 
regions, colored bars indicate variant exons inserted into final transcripts by alternative splicing. EC, 
extracellular domain, TM, transmembrane domain, CP, cytoplasmatic domain. (B) Examples of variant CD44 
isoforms. (Adapted from (Zoller, 2011)). 
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The amino-terminal globular structure is responsible for HA binding through two 
binding sites: the link domain (amino acids 32-132) and a basic motif outside the link domain 
(amino acids 150-158) (Aruffo et al., 1990; Screaton et al., 1992). The amino-terminal 
domain can also interact with several additional molecules including other 
glycosaminoglycans (GAGs), laminin, fibronectin and collagen (Naor et al., 1997). It is 
extensively modified by N- and O-linked glycosylation, which influences the affinity for the 
different CD44 ligands. With the insertion of variant exon products new sites for secondary 
modification are introduced. For instance, sequence encoded by exon v3 has sites for 
modification with chondroitin sulfate or heparin-sulfate to which several heparin-binding 
proteins such as fibroblast growth factor 2 (FGF2) can bind (Bennett et al., 1995). CD44v6 
contains a binding site for hepatocyte growth factor (HGF) and vascular endothelial growth 
factor (VEGF) (Orian-Rousseau and Ponta, 2008; Tremmel et al., 2009). Moreover, CD44 
isoforms containing the sequences encoded by the exons v6 and v7 interact with osteopontin 
(Katagiri et al., 1999). CD44 can also bind through its GAG binding sites to proteoglycans, 
such as versican (Kawashima et al., 2000), aggrecan (Fujimoto et al., 2001), and serglycin 
(Toyama-Sorimachi et al., 1995). However, the functional relevance of these interactions still 
needs to be clarified.   
Dynamic regulation of the interaction between CD44 and the extracellular matrix 
during cell migration is brought about shedding of the ectodomain of CD44 by proteolytic 
cleavage within the stem structure (Okamoto et al., 1999ba). It is triggered by multiple signals 
including the influx of extracellular Ca
2+
, the activation of protein kinase C (PKC), Rho 
family of small GTPases, Rac and Ras oncoproteins (Okamoto et al., 1999ab). This cleavage 
is mediated by matrix metalloproteinases (MMPs), such as MT1-MMP, ADAM10 and 
ADAM17.  
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Figure 7: Protein structure and interactions of CD44. The CD44 protein consists of an extracellular, 
a single transmembrane and a  cytoplasmatic domain. The extracellular domain includes the N-terminal - and the 
stalk region close to the transmembrane domain. This region varies in different isoform due to splicing of the 
variant exons in different combinations in a tissue specific manner. The ectodomain contains binding sites for 
HA enables its interaction with growth factors, growth factor receptors and matrix metalloproteinases. Multiple 
sites for N-glycosylation (black circles) and O-glycosylation (orange circles) exist in this domain. There are two 
GAG binding sites (yellow circles), one of which is located in a CD44 domain encoded by  exon v3. The 
cytoplasmatic tail includes the ERM (dark blue) and ankyrin-binding (light blue) domains, as well as binding 
motives for Src phosphokinases lck, lyn and fyn. S-S, disulphide bonds. (Adapted from (Misra et al., 2011; 
Zoller, 2011)).  
 
The transmembrane domains of individual CD44 molecules associate with each other 
in oligomers and with lipid rafts (Neame et al., 1995; Perschl et al., 1995). 
Interactions of the C-terminal cytoplasmatic tail with ankyrin and members of the 
ERM (ezrin, radixin and moesin) family of proteins link CD44 with the cytoskeleton 
(Kalomiris and Bourguignon, 1989; Tsukita et al., 1994). Phosphorylation of serine residues 
in this domain, mediated by protein kinase C, modulates interactions of CD44 with ERM 
proteins. Phosphorylation of Ser-291 abrogates ezrin binding and modulates CD44-mediated 
directional cell motility (Legg et al., 2002). Merlin, a tumor suppressor  structurally related to 
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the ERM family, also associates with the cytoplasmic tail of CD44. Dephosphorylation of 
merlin, which is associated with its growth inhibitory function, is provoked by high cell 
density or addition of high-molecular weight HA and depends on its interaction with the 
cytoplasmatic tail of CD44 (Morrison et al., 2001; Shaw et al., 1998). Moreover, intracellular 
signaling molecules, such as kinases Src, LCK, Fyn, Rho GTPase, Rho kinase and the 
nucleotide exchange factors TIAM1 and VAV2, also associate with the intracellular C-
terminal domain of CD44 (Naor et al., 1997; Ponta et al., 2003), but the nature and the 
functional relevance of these interactions are not yet understood in detail. 
3.3.2  CD44 in cancer 
CD44 has been reported to be essential for many tumor activities and its expression in 
tumor tissue was shown to be associated with increased metastatic spread in different types of 
cancer. Over the last decade, numerous studies have addressed the relevance of CD44 
isoforms as prognostic factors for human cancers. The results suggested that, depending on 
the affected organ, the pattern of CD44 isoforms expression and the occurrence of metastases 
are directly or inversely related. The expression of various CD44 isoforms was found 
upregulated in many human tumor types, including gastric cancer, pancreatic cancer, lung and 
renal cell cancer (Heider et al., 1993; Lim et al., 2008; Penno et al., 1994; Rall and Rustgi, 
1995). The results of several reports point to important functions of the standard form of 
CD44 (CD44s) in tumor progression (Cannistra et al., 1993). However, in other tumor types 
as neuroblastoma and prostate cancer, the lack of CD44 expression (both the standard isoform 
and the splice variants) indicated poor prognosis (Angelo M. De Marzo, 1998; Shtivelman 
and Bishop, 1991) and CD44 even acts as a metastasis-suppressor gene in prostate carcinoma 
cells (Gao et al., 1997; Ponta et al., 2003). 
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3.3.3 CD44 mechanisms of action  
Three types of molecular actions underlie the multifunctionality of CD44 (Ponta et al., 
2003).  First, ectodomains of CD44 molecules on the cell surface act as receptors for ligands 
of the ECM, predominantly HA, and form “platforms” that orchestrate the assembly of cell 
surface protein complexes that include matrix metallo-proteinases and growth factors. 
Second, they are co-receptors of several receptor tyrosine kinases and thereby modulate the 
signaling of associated growth factor receptors. Third, they act as organizers of the actin 
cytoskeleton.  
Consequently, adhesiveness, motility, matrix degradation, proliferation and cell 
survival can be modulated by CD44 through interplay with its ligands and associated 
molecules.  CD44 mediated regulation of these cellular processes enables the tumor cells to 
successfully proceed through all the steps of the metastatic cascade (Marhaba and Zoller, 
2004).  
3.3.3.1 CD44 as a ligand-binding surface receptor 
As outlined before, a predominant property of CD44 is its ability to bind HA. The HA 
binding sites are located in the standard part of the CD44. Importantly, insertion of variant 
exon products or the state of glycosylation may influence the affinity of the binding.  
Interestingly, not all CD44 expressing cells are capable to bind HA. In many cases, 
CD44 doesn’t bind to HA unless activated by external stimuli. Through this mechanism 
unnecessary engagement of the receptor is avoided, since both the ligand and the receptor are 
ubiquitously expressed. CD44 molecules are apparently expressed at the cell surface in three 
states of variable activity (reviewed in (Naor et al., 2002)):  
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 Active CD44, which binds HA constitutively; 
 Inducible CD44, that binds HA upon activation by different stimuli, including 
cytokines (interleukin 5, tumor necrosis factor α), growth factors (EGF), 
oncostatin M and phorbol ester. The binding can also be induced by CD44 
crosslinking, which results in either conformational changes or redistribution 
of CD44 in the plasma membrane; 
 Inactive CD44, which is unable to bind to HA, even in the presence of 
inducing agents.  
Despite extensive research, there are still conflicting data regarding the importance of 
CD44-HA interaction in the regulation of tumor malignancy. CD44 has been shown to 
promote tumor and metastasis development both in a HA-dependent and HA-independent 
fashion. Several lines of evidence indicated that CD44 mediated binding of cancer cells to 
HA-rich ECM triggers cell signaling pathways that regulate the migration, invasion and 
lodging of tumor cells in distant organs (Misra et al., 2011; Thomas et al., 1992). Yu et al. 
demonstrated the role of CD44-HA interaction in promoting tumor invasion (Yu et al., 1997). 
In their study, overexpression of a soluble CD44 ectodomain in murine metastatic mammary 
carcinoma cells suppressed the binding and internalization of HA by endogenous cell surface-
located CD44 and, consequently, the invasion on HA-producing cell monolayers. In an 
experimental metastasis model in mice, intravenously injected CD44 ectodomain-
overexpressing cells, unlike non-transfected control cells, formed only a few or no metastases 
in the lungs. Both cell types adhered to the pulmonary endothelium and were able to penetrate 
the interstitial stroma, but the mammary carcinoma cells overexpressing the soluble CD44 
ectodomain underwent apoptosis. These data indicate that one of the mechanisms, by which 
CD44-HA interaction supports the metastatic process, is the inhibition of apoptosis. In a 
comparable study with a human melanoma cell line, Ahrens et al. demonstrated that 
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overexpression of soluble HA binding CD44 suppressed subcutaneous primary tumor growth 
in mice, whereas cells overexpressing HA binding-defective soluble CD44 formed fast 
growing subcutaneous tumors much like the non-manipulated human melanoma cells (Ahrens 
et al., 2001). These results implicate that the observed growth inhibition is dependent on the 
interaction between soluble CD44 and HA, which competes for the interaction of HA with 
endogenous CD44 on the cell surface.  
 In contrast, transfection of a pancreatic carcinoma cell line with a CD44v4-v7 isoform 
conferred metastatic activity (Günthert et al., 1991) independent of HA binding, since 
removal of HA by degradation had no impact on the metastatic potential of CD44v4-v7 
overexpressing cells (Sleeman et al., 1996). 
3.3.3.2 CD44 as a “platform” for enzymes and substrates 
It has been described that CD44 proteins concentrate MMPs, such as MMP7 (Yu et 
al., 2002) and MMP9 (Yu and Stamenkovic, 1999), on the cell surface. For example, CD44-
HA aggregates facilitated recruitment of MM9 to the cell surface of mouse mammary 
carcinoma and human melanoma cell lines and thereby promoted degradation of collagen IV 
and tumor-cell invasion (Yu and Stamenkovic, 1999). Furthermore, in addition to collagen 
degradation, MMP9 is also responsible for proteolytic activation of TGFβ (tumor growth 
factor β) that triggers angiogenesis (Yu and Stamenkovic, 2000). Similar to MMPs, a variety 
of growth factors and cytokines are also immobilized on the cell surface through interaction 
with CD44. Examples have been described before.  
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3.3.3.3 CD44 as a co-receptor 
An emerging concept in signal transduction nowadays is that cell-adhesion molecules, 
once believed to primarily act as cell surface molecules attaching cells to extracellular 
ligands, have additional functions as co-receptors in cellular signaling cascades (Ponta et al., 
2003). 
Accordingly, the CD44 isoforms containing an exon v6 encoded domain are essential 
for the activation of c-Met by HGF/SF and was found to form a complex with the ligand and 
its cognate receptor in a rat and in human carcinoma cell lines, as well as in primary 
keratinocytes. Furthermore, the cytoplasmatic tail of CD44 is required for further signal 
transduction from activated c-Met (Orian-Rousseau et al., 2002). A second interaction, 
relevant in tumor cells, was observed between CD44 and receptor tyrosine kinases of the 
ERBB receptor family. CD44 co-immunoprecipitates with ERBB1 (EGFR/HER1), ERBB2 
(HER2/neu), ERBB3 (HER3) and ERBB4 in several cell lines and primary cells 
(Bourguignon et al., 1997; Sherman et al., 2000; Yu et al., 2002). Moreover, the heparin-
binding epidermal growth factor (HBEGF) preform binds to CD44v3 modified by heparin-
sulphate side chains, and it is subsequently cleaved by MMP7, which is recruited to the cell 
surface by CD44. Cleaved HBEGF then activates its receptor ERBB4 that signals for cell 
survival (Yu et al., 2002). CD44, on the other hand, also mediates, through direct interaction, 
the heterodimerization of ERBB2/ERBB3 in response to neuregulin. The resulting receptor 
activation is crucial for differentiation, survival and proliferation of Schwann cells (Meyer 
and Birchmeier, 1995; Riethmacher et al., 1997; Sherman et al., 2000). 
  
30 
  
 
3.3.3.4 CD44 as an organizer of the cytoskeleton 
The interaction of CD44 with the actin cytoskeleton is indirect and is achieved via 
linker proteins, including ankyrin and the members of the ERM family (Bourguignon et al., 
1998; Tsukita et al., 1994). Ankyrin mediates the contact with spectrin and plays a role in 
HA-dependent cell adhesion and motility (Lokeshwar et al., 1994). ERM proteins are 
involved in the regulation of cell migration, cell shape determination and membrane-protein 
localization (Bretscher et al., 2002). CD44, through interaction with these linker proteins, also 
influences these diverse cellular processes.  
3.3.4 CD44 and cancer stem cells 
 Cancer stem cells (CSC) or cancer initiating cells (CIC) are defined as a minor 
population of cells within a tumor that display stem-cell properties (Zoller, 2011). They can 
self-renew, differentiate into different lineages and reconstitute the heterogeneous phenotype 
of the parental tumor they were derived from in serial xenotrasplant assays (Stamenkovic and 
Yu, 2009). These cells are highly chemoresistant and are thought to be essential for metastasis 
formation.   CD44 has been identified as one of the most common markers of CSCs in many 
tumor entities, including leukemia, breast, colon, ovarian, prostate and pancreatic cancer 
(Croker and Allan, 2008). 
3.3.5 CD44 in osteosarcoma 
Little is known about the contribution of CD44 to OS progression and metastasis. Two 
immunohistochemical studies with osteosarcoma tissue specimens came to different 
conclusions. Kim et al. reported that overexpression of CD44v5 in tumor tissue correlated 
significantly with metastasis and lower survival rates (Kim et al., 2002). An analysis of tumor 
samples by Kuryu et al. found a correlation between the overexpression of CD44 isoforms 
containing variant v6 and poor prognosis (Kuryu et al., 1999). In both studies, the expression 
of total CD44 did not correlate with prognosis. Recent reports, also aiming at determining the 
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prognostic value of CD44 expression in OS, failed to find a correlation between CD44 gene 
or protein expression in OS tumor specimens and overall survival.  However, Xu-dong et al. 
observed that OS patients with high expression of CD44 gene were more prone to have 
metastases (Boldrini et al., 2010; Xu-Dong et al., 2009). Before drawing conclusions, we have 
to be aware that most of the studies performed the analysis in tumor tissue of a relatively 
small number of patients. Thus, large cohorts of samples need to be analysed to determine the 
potential association of CD44 with other clinicopathological variables and its possible use as a 
predictor of prognosis. 
Weber et al. examined in mice the effects of targeted deletion of the CD44 gene on the 
spontaneous development of endogenous different tumors caused by mutations in tumor 
suppressor genes (min mutation of the APC gene and tm1 mutation of the p53 gene)  (Weber 
et al., 2002).  Mice with an APC 
+/min
 genotype were found to be predisposed to develop 
multiple benign intestinal tumors, whereas mice with trp53 
+/tm1
 genotype are susceptible to a 
larger spectrum of tumors, predominantly sarcomas and lymphomas. When CD44-null mice 
were crossed with mice carrying tm1 mutation of the p53 gene, the animals developed 
osteosarcomas and only one individual lung metastases was detected in 4 CD44 
-/-
 mice. All 6 
CD44 
+/+
 mice had multiple osteosarcoma-derived metastases. The absence of the CD44 gene 
in trp53 
+/tm1
 mice had no effect on the tumor incidence and tumor weight, as well as the life 
span of these animals. The phenotype of benign tumors formed in APC 
+/min
 mice was not 
altered by the absence of CD44. This study supported the idea that CD44 is crucial for 
metastasis promotion, but not for initiation of tumorigenesis. However, bearing in mind the 
low number of experimental animals analyzed in these studies, the results might have been 
over-interpreted. 
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In a differently designed study, Shiratori et al. showed that lipopolysaccharides, a 
proinflammatory mediator,  up-regulated the expression of CD44 in murine POS-1 OS cells, 
which accelerated lung metastasis in a syngeneic mouse model (Shiratori et al., 2001). 
Interestingly, gain or loss-of function studies investigating the role of CD44 in OS in 
established cell lines or xenograft mouse models have so far not been reported. 
 
3.4 Hyaluronan 
Hyaluronan (HA, hyaluronic acid) is an extracellular and cell-surface associated linear 
glycosaminoglycan, composed of repeating disaccharides of glucuronic acid and N-acetyl-
glucosamin (Figure 8). The number of alternating units can vary depending on the tissue 
source and the physiological conditions, but usually HA molecules contain between 2000 and 
25000 disaccharides, corresponding to molecular weights of between 10
6
 and 10
7
 Da and a 
length of 2-25 µm. In contrast to other glycosaminoglycans, HA does not include heparin 
sulphate and chondroitin sulphate and is not covalently bound to a core protein. It has a 
ubiquitous tissue distribution in vertebrates, both in the embryo and the adult, however, it is 
especially accumulated in pericellular matrices surrounding proliferating and migrating cells, 
e.g. during embryonic morphogenesis and in inflammation, wound repair and cancer (Toole, 
2004). 
 Hyaluronic acid is produced by hyaluronan synthases (HAS1, HAS2, HAS3) that are 
integral plasma membrane proteins. Simultaneously with the synthesis process, HA polymers 
are directly extruded through the plasma membrane into the extracellular space. They can be 
retained at the cell surface by HA synthases or through binding to receptors (CD44, 
RHAMM, lymphatic vessel endothelial receptor, layilin, and Toll-like receptor-4 (Bono et al., 
2001; Termeer et al., 2002; Turley et al., 2002). Hyaluronan is degraded by the hyaluronidase 
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family of enzymes, some of which are considered as tumor suppressors (Frost et al., 2000). 
HA fragmentation also occurs through reaction with reactive oxygen species (Yamazaki et al., 
2003). Products generated were shown to induce angiogenesis or to provoke cleavage of 
CD44, thereby promoting motility and invasion (Sugahara et al., 2006; West et al., 1985). 
 
 
Figure 8: Chemical structure of hyaluronic acid. 
Numerous biological actions of HA result from its extraordinary biophysical and 
interactive properties. HA contributes to tissue homeostasis and biomechanical integrity 
through its negative charge characteristics and its ability to retain water. Its interactions with 
proteoglycans and other extracellular macromolecules are crucial for the assembly and 
organization of extra- and pericellular matrices (Toole, 2002). Through binding to specific 
receptors, such as CD44 and RHAMM, HA stimulates signal transduction, either directly or 
by activating other receptors, and thereby influences cell behavior in various morphogenetic 
and physiological systems (Turley et al., 2002). For example, CD44 on cancer cells interacts 
with HA-rich microenvironments. This triggers cell signaling pathways that regulate 
migration and invasion of malignant cells through ECM and lodging at distant sites (Misra et 
al., 2011). 
  
Glucuronic acid N-acetyl-glucosamine 
 
34 
  
 
3.4.1 HA in tumor progression 
Numerous studies over the last few decades revealed evidence for a tumor promoting 
role of HA, both in animal models and in cancer patients. It is well established that increased 
levels of HA, both in tumor cells and in the peritumoral stroma, are prognostic for malignant 
progression. In patients suffering from breast, ovarian or prostate cancers, high HA levels in 
tumor stroma were found associated with unfavorable outcome (Anttila et al., 2000; Auvinen 
et al., 2000; Lipponen et al., 2001). Increased amounts of HA have also been observed in the 
urine of bladder carcinoma patients (Lokeshwar et al., 2002), in the serum of breast cancer 
patients (Delpech et al., 1990) and in the saliva of patients with head and neck cancer 
(Franzmann et al., 2003). However, no correlation was found between the HA levels in 
melanoma tissue and tumor  progression (Karjalainen et al., 2000). 
The results of studies in animal models investigating the role(s) of HA in tumor 
progression are contradictory. Several approaches have been used to prove the contribution of 
HA to tumor progression, such as manipulation of HA levels and perturbation of endogenous 
HA-protein interactions in various ways. Overexpression of HAS1, HAS2 or HAS3 followed 
by overproduction of HA in tumor cells resulted in increased growth or metastatic activity of 
tumors in xenograft models of fibrosarcoma (Kosaki et al., 1999) and of prostate (Liu et al., 
2001), breast (Itano et al., 1999) and colon cancer (Jacobson et al., 2002). Additional 
experimental proof for a tumor-promoting role of HA was obtained in studies, which 
demonstrated that overexpression of hyaluronidases suppressed the growth of colon and 
breast carcinoma xenografts (Jacobson et al., 2002; Shuster et al., 2002). However, some 
reports claim the contrary and provide evidence for a tumor-promoting effect of 
hyaluronidase overexpression  in astrocytoma and prostate cancer cell lines (Novak et al., 
1999; Patel et al., 2002). These findings obtained in experimental tumor models are consistent 
with clinical data indicating increased levels of hyaluronidase (usually HYAL1) in bladder 
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(Hautmann et al., 2001), prostate (Posey et al., 2003) , head and neck (Franzmann et al., 2003)  
and brain cancer (Delpech et al., 2002). 
All findings taken together emphasize an important regulatory role of HA in cancer 
progression. 
3.4.2 HA in osteosarcoma 
Several groups investigated the impact of HA on osteosarcoma progression. The study 
of Nishida et al. (Nishida et al., 2005) revealed that inhibition of HAS2 expression in human 
MG63 OS cells by antisense phosphorothioate oligonucleotides reduced HA production and 
resulted in the disruption of cell-associated matrices assembly and, consequently, in decreased 
cell proliferation, motility and invasive capacities. Tofuku et al. found that HA synthesized by 
HAS3 promoted biological functions crucial for metastasis, such as proliferation, invasion and 
degradation of extracellular matrix. 4-methylumbelliferon (4-MU), an inhibitor of HA 
synthesis, was shown to inhibit both proliferation and invasion of LM8 cells in vitro (Tofuku 
et al., 2006). Hosono et al. (Hosono et al., 2007) examined the effects of HA oligosaccharides 
on tumorigenicity of LM8 murine OS cells and MG63 human osteosarcoma cells. They 
reported that treatment with HA octamers suppressed the formation of cell-associated matrix, 
which resulted in the inhibition of growth, motility and invasiveness and the induction of 
apoptosis in vitro in both cells lines. In in vivo studies with LM8 cells subcutaneously 
injected into syngeneic mice, intratumoral injection of HA oligosaccharides reduced the 
accumulation of HA in tumor tissue and resulted in significant suppression of lung metastasis. 
In a recent study, the same group showed that 4-MU effectively inhibits various processes of 
tumorigenicity in vitro in murine LM8 and human MG63 and HOS OS cells. Administration 
of 4-MU in vivo markedly suppressed lung metastasis of the highly metastatic LM8 OS cells 
(Arai et al., 2011). 
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Taken together, these reports highlight the involvement of HA in the progression and 
metastasis of OS. 
3.5 Aim of the Thesis 
CD44 is a multifunctional protein that has been implicated in different aspects of 
tumor progression, especially with the metastatic spread of different types of cancer as 
described above. CD44 is the principle receptor for HA, and their interaction promotes the 
malignant behavior of various tumor cell types, whereas it is not essential for the metastatic 
behavior of other tumor cell types. The overall aim of this thesis was to investigate the 
contribution of CD44 and HA interaction to OS primary tumor development and metastasis. 
In order to accomplish our goal to gain better understanding on the role of CD44 and HA 
interaction in OS biology we had to complete two specific objectives. 
The first objective was to estimate the prognostic value of CD44 expression for OS 
patients’ outcome. 
The second objective was to explore the biological relevance of CD44 and HA 
interaction for in vitro malignant properties of OS tumor cells and for in vivo OS progression 
and metastasis using several orthotopic xenograft OS mouse models.  
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ABSTRACT 
Formation of metastases in the lungs is the major cause of death in patients suffering from 
osteosarcoma (OS), a disease mainly affecting children and adolescents. Metastases at 
presentation and poor response to preoperative chemotherapy are strong predictors for poor 
patient’s outcome. The elucidation of molecular markers that promote metastasis formation 
and/or chemoresistance is therefore of importance. CD44 is a plasma membrane glycoprotein 
that binds to the extracellular matrix component hyaluronan (HA) and has been shown to be 
involved in metastasis formation in a variety of other tumors. Here we investigated the role of 
CD44 expression on OS tumor formation and metastasis. High CD44 expression, evaluated 
with a tissue microarray including samples from 53 OS patients and stained with a pan CD44 
antibody (Hermes3), showed a tendency (p < 0.08) to shortened overall survival. However, 
non-responders and patients with lung metastases and high CD44 expression had significantly 
poorer prognosis than patients with low CD44 expression. Overexpression of CD44 (standard 
isoform CD44s) and its hyaluronan binding defective mutant R41A in osteoblastic SaOS-2 
cells resulted in HA-independent higher migration rates and increased chemoresistance, 
partially dependent on HA. In an orthotopic mouse model of OS, overexpression of CD44s in 
SaOS-2 cells resulted in a HA-dependent increased primary tumor formation and increased 
numbers of micro- and macrometastases in the lungs. In conclusion, although CD44 failed to 
be an independent predictor for patient’s outcome in this limited cohort of OS patients, 
increased CD44 expression was associated with even worse survival in patients with 
chemoresistance and with lung metastases. CD44 associated chemoresistance was also 
observed in vitro, and increased formation of lung metastases was found in vivo in SCID 
mice.  
 
KEY WORDS: CD44; CHEMORESISTANCE; HYALURONAN; METASTASIS; 
OSTEOSARCOMA  
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Introduction  
Osteosarcoma (OS) is the most common primary tumor of bone in children and adolescents. 
The presence of malignant spindle cells that produce osteoid and/or immature bone is 
characteristic for this highly aggressive cancer type.
(1)
 The incidence of OS in the general 
population is 3 cases per million per year, but is higher in adolescence, in which it reaches 8-
11 cases/million/year at 15-19 years of age.
(2)
 OS has a great tendency of spreading to the 
lungs, and less frequently to the bones. Formation of bone metastases occurs only after 
pulmonary metastases have already been established.
(3)
 At the time of diagnosis, up to 15-
20% of patients already have detectable metastases. However, 80% of patients initially 
presenting with localized disease develop metastases after surgical resection.
(4)
 Combination 
of multi-agent chemotherapy with surgery introduced in late 1970’s remarkably improved the 
overall survival of patients with non-metastatic disease, whose 5-year survival rate is now 
70%, as opposed to only 20% few decades ago. In contrast, the patients with metastatic or 
recurrent disease did not benefit from these clinical advances and they unfortunately face a 
very poor prognosis, with a survival rate that remains still at 20%.
(5)
 The failure of treatment 
in these patients is often associated with gained resistance to chemotherapy.
(6)
 Nowadays, the 
most powerful and reproducible prognostic indicators for OS patients are metastatic lesions at 
presentation and histological response to preoperative chemotherapy.
(7)
 Thus, it is of 
substantial relevance to identify molecular markers associated with the increased metastatic 
potential or chemoresistance, which may serve as diagnostic or prognostic factors. Acquiring 
insight into the basic biology of OS progression will make the identification of such new 
therapeutic targets possible with the final goal to develop treatment strategies that eradicate 
metastases, the major cause of death in OS. 
CD44 has been linked with increased metastatic spread in various types of cancer.
(8)
 CD44 
designates a family of broadly distributed type I transmembrane glycoproteins that serve as 
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cell-cell and cell-matrix adhesion molecules and as principal receptors for hyaluronan (HA), a 
major component of the extracellular matrix in many tissues including bone.
(9)
 Existence of 
multiple isoforms, generated through alternative splicing, and extensive post-translational 
modifications underlie the wide repertoire of CD44 biological functions in development, 
wound healing, inflammation, hematopoiesis, immune response and tumor progression.
(10)
  
Tissue-specific splicing results in the formation of the standard CD44 isoform (CD44s), 
lacking all variant exons, in cells of mesenchymal origin and, thus, the expression of this 
isoform may be relevant for sarcoma tumor progression.
(11,12)
 CD44 has been shown to 
promote tumor and metastasis development both in a HA-dependent and HA-independent 
fashion.
(13,14)
  Both CD44 and HA have been implicated in resistance to anticancer drugs.
(15-17)
 
Only few immunohistochemical studies using OS tissue specimens addressed the contribution 
of CD44 to OS progression and metastasis giving rise to conflicting data.
(18-20)
 Interestingly, 
gain or loss-of function studies investigating the role of CD44 in established OS cell lines or 
xenograft mouse models, to our knowledge, have so far not been reported.  On the other hand, 
a limited number of reports indicated the relevance of HA in OS tumor progression after 
making use of established cell lines. Treatment with HA oligosaccharides suppressed the 
formation of cell-associated matrix, leading to inhibited tumorigenicity of the human MG63 
and murine LM8 OS cell lines in vitro.
(21)
 In in vivo studies, intratumoral injection of HA 
oligosaccharides into subcutaneous LM8-derived tumors reduced the accumulation of HA in 
tumor tissue and resulted in significant suppression of lung metastases.
(21)
 In vivo 
administration of 4-methylumbelliferon, an inhibitor of HA synthesis, inhibited the retention 
of HA in the periphery of the primary tumors and markedly reduced the number of metastatic  
lung lesions formed by LM8 OS cells.
(22)
 
In our current study we show that CD44 can be used as an additional prognostic factor for OS 
patients’ outcome. With the aim to investigate the biological relevance of CD44s expression 
Gvozdenovic et al. 4 
 
and its’ interaction with HA for OS progression and metastasis,  we overexpressed the CD44s 
isoform and its’ HA-binding defective mutant CD44s R41A in the low metastatic human OS 
SaOS-2 cells, that display an osteoblastic phenotype most commonly observed in human 
patients. Using an intratibial xenograft OS mouse model we demonstrated that CD44 standard 
isoform enhances primary tumor growth and formation of pulmonary metastases in a HA-
dependent manner. In conclusion, the results presented here highlight CD44-HA interaction as 
a potential target for therapeutic intervention in OS. 
Materials and Methods 
Human OS tissue microarray analysis  
OS tissue specimens were collected between June 1990 and December 2005 from 53 patients 
during primary tumor resection in accordance with the regulations of the local ethic 
committee. Clinical data of the patients are presented in Table 1. All patients received 
neoadjuvant chemotherapy and the subsequent response was determined histologically on 
resected tumor specimens according to Salzer-Kuntschik.
(23)
 Grades I, II and III were 
considered as a good response, whereas grades IV, V and VI were classified as a poor 
response. The tissue microarray was arranged as described.
(24)
 Microarray sections of 4.5 µm 
were processed as reported 
(25)
 and stained with a pan-CD44 antibody Hermes3 (generously 
provided by Dr. S. Jalkanen, Turku, Finland) (1:1000) and counterstained with hematoxylin. 
Tissue microarray grading was performed based on the intensity and area percentage of the 
positive stain using Table 1 in Supplemental Data. The intensity of the stain was judged by 
eye (week, moderate and strong). The percentage of staining was calculated using a custom 
MATLAB (v2009b, Mathworks, MA) program. Positive (brown) and negative (blue) staining 
were separated using color deconvolution theory.
(26)
 The area percentage of the stain was 
defined as positive stained area (number of brown pixels) over total tissue area (number of 
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blue and brown pixels) (Fig. 1, Supplemental Data). Kaplan-Meier analysis was used to 
correlate CD44 expression with overall and event-free survival of OS patients.  
Cell culture and transduction  
Human OS SaOS-2 (HTB-85) cells obtained from American Type Culture Collection (ATCC, 
Rockville, MD, USA), were cultured in DMEM (4.5 g/l glucose)/HamF12 (1:1) medium 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10  heat inactivated FCS at  7  C in a 
humidified atmosphere of 5% CO2/95% air. In order to enable visualization of tumor cells 
within mouse tissues, SaOS-2 cells were transduced with LacZ gene (SaOS-2/LacZ cells) as 
described recently.
(27)
 Stable expression of the standard CD44 isoform (CD44s) and its’ HA 
binding-defective mutant CD44s R41A was achieved by retroviral gene transfer. Briefly, 
pMSCV vectors containing human CD44s and CD44s R41A coding sequences, generously 
provided by Prof. Stamenkovic (Lausanne, Switzerland), were used to fuse V5 and His6 
epitopes to the COOH-terminal ends of CD44s and CD44s R41A giving rise to CD44s-
V5/His6 and CD44s R41A-V5/His6 encoding sequences that were subsequently subcloned 
into the retroviral expression vector pQCIXH (Clontech, Paolo Alto, CA, USA) containing a 
hygromycin resistance gene. All expression constructs were verified by sequencing of both 
strands. Retroviral particles containing pQCIXH EV (empty vector), pQCIXH CD44s-
V5/His6 and pQCIXH CD44s R41A-V5/His6 were produced in HEK 293T cells, and were 
subsequently used to infect SaOS-2/LacZ cells as described.
(27)
 Selection for hygromycin 
resistance in medium containing 400 µg/ml of hygromycin (Calbiochem, Switzerland) 
revealed SaOS-2 EV, SaOS-2 CD44s and SaOS-2 CD44s R41A cell lines.  
Western blot analysis  
Cells were lysed by agitation on a carrousel at 4  C for 1h in lysis buffer containing 50 mM 
Tris/HCl (pH 7.5), 150mM NaCl, 1% NP40, 0.5% deoxycholic acid, 0.1% sodium dodecyl 
sulfate (SDS), 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulphonyl fluoride (PMSF) 
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and 10 mg/ml aprotinin. Cellular debris were removed by centrifugation at 13 000 rpm and 
4  C for  0 minutes. Equal amounts of proteins of individual cell extracts were separated by 
8% SDS-PAGE. The proteins were then transferred by semi-dry blotting to Hybond-ECL 
membranes (GE Healthcare, UK). Endogenous and V5-tagged CD44 proteins and GAPDH 
were visualized with respective mouse monoclonal Hermes3 antibody (concentration 1µg/ml), 
V5 antibody (1:5000; Invitrogen) and rabbit polyclonal anti-GAPDH antibody (1:3000; Santa 
Cruz Biotechnologies, CA, USA) and corresponding HRP-conjugated secondary antibodies 
purchased from Santa Cruz Biotechnologies. Peroxidase activity was detected with the 
Immobilon chemoluminescence substrate (Millipore, Billerica, MA, USA) and a VersaDoc
TM 
Imaging System (Bio-Rad, Hercules, CA, USA). 
Adhesion assay  
96-well plates were coated with 333 µg/cm
2 
of high molecular weight HA (HMW-HA) 
(Sigma-Aldrich, St. Luis, MO, USA) at 4  C over night. They were then washed with PBS and 
blocked with heat-denatured 1% BSA (HD-BSA). Non-coated wells or wells coated with HD-
BSA alone were used as controls. Adhesion assays were carried out with cells grown in tissue 
culture medium to subconfluency in 25cm
2
 tissue culture flasks. They were then detached 
with accutase (Sigma-Aldrich), resuspended in medium and seeded at 10
4
 cells per well and 
allowed to adhere at  7  C for 30 minutes. In CD44 blocking experiments, adhesion was 
performed in the presence of 10 µg/ml  Hermes1 antibody (kindly provided by  Dr. S. 
Jalkanen, Turku, Finland)  that blocks HA binding or of 10 µg/ml  rat IgG2A antibody (R&D 
Systems, Minneapolis, MN, USA) as a control.  Non-adherent cells were removed by washing 
with PBS and adherent cells were fixed with 10% formalin in PBS at room temperature (RT) 
for 15 min and then stained with 0.05% crystal violet in H2O at RT for 15 min. Images of 
randomly selected areas of 3.6 mm
2
 were taken with an AxioCam MRm camera connected to 
the Zeiss Observer.Z1 inverted microscope (Carl Zeiss MicroImaging GmbH, Göttingen, 
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Germany) set at at 4x magnification. The number of adherent cells in the analyzed area was 
estimated with ImageJ software. The total number of adherent cells per well was calculated 
and the percentage of adherent cells was obtained by dividing the number of adherent cells by 
the total number of seeded cells and multiplying with 100. The experiments were performed 
in triplicates and repeated three times. 
Transwell migration assay  
Cell culture inserts (Becton Dickinson, San Jose, CA, USA) with 8 µm porous filters in 24-
well plates were used for a transwell migration assay. Cells grown to subconfulency were 
detached with accutase (Sigma-Aldrich) and 2 x 10
4
 cells in 300 µl of serum-free cell culture 
medium supplemented with penicillin/streptomycin/amphotericin B (PSA, 1:100; Invitrogen) 
were added to the upper compartment of the inserts. The lower compartments were filled with 
700  l of medium containing 10  FCS complemented with PSA. After incubation at  7  C for 
24h, non-migrating cells on the upper side of the insert were removed with a cotton swab.  
Cells that had migrated to  the lower side of the filters were fixed with 10% formalin, 
permeabilized with 50 µM digitonin (Calbiochem, Switzerland) and stained with 300 nM 
Picogreen in PBS (1:200; Invitrogen) at RT for 15 min. Three images per insert (two inserts 
per cell line) showing an area of 0.58 mm
2
  were taken with an  AxioCam MRm camera 
connected to the Zeiss Observer.Z1 inverted microscope adjusted to 10x magnification and 
equipped with an appropriate filter block for blue excitation. The number of cells on the 
images was counted with the ImageJ software, and the percentage of migrated cells was 
calculated as described for the adhesion assay. The experiments were performed at least three 
times. 
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In vitro cell proliferation assay 
Subconfluent cells in the logarithmic growth phase were trypsinized and 5 x 10
4
 cells, 
resuspended in 2.5 ml of cell culture medium, were seeded in 12.5 cm
2
.The cells were 
allowed to grow for between 1 and 7 days and counted in intervals of 48 hours in triplicates. 
Cells in individual flasks were detached by trypsinization and counted in a Neubauer 
chamber. The doubling time during logarithmic growth was calculated according to the 
equation N=No e
kt
 (N0= number of seeded cells; N=number of cells at time t). The 
experiments with individual cell lines were carried out three times. 
Cytotoxicity assay 
3 x 10
3
 cells per well were seeded in 96-well plates and allowed to adhere overnight. The cells 
were then incubated in duplicates with increasing concentrations of cisplatin (0.01 - 25 
µg/ml), doxorubicin (0.01 – 6 µg/ml) and etoposide (0.05 – 250 µg/ml) for 72h. All drugs 
were purchased from Sigma-Aldrich. After the drug treatment, the cells were incubated with 
10 µl/well of WST-1 reagent (Roche, Switzerland) for 3 hours and the cell viability was then 
assessed as reported.
(28)
 Prism 4 network software was used to calculate the half-maximal 
growth inhibitory concentration (IC50) of the drugs. The experiments were repeated three 
times. 
Intratibial OS xenograft model in SCID mice 
The animal experiments were performed as described 
(25)
 according to the guidelines of the 
“Schweizer Bundesamt für Veterinärwesen” and as approved by the authorities of the Kanton 
Zürich. Briefly, on day 0 of the experiment, 5 x 10
5
 of SaOS-2 cells engineered as indicated 
were suspended in 10 µl of PBS/0.05% EDTA and injected intratibially into SCID/CB17 
immunocompromised mice obtained from Charles River Laboratories (Sulzfeld, Germany). 
After the injection, the health condition of the mice was closely monitored. The development 
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of primary tumors was visualized bi-weekly during the first 1 to 9 weeks of the experiment 
and then weekly until the end of the experiment by X-ray with a MX-20 DC Digital 
Radiography System (Faxitron X-Ray Corporation Lincolnshire, IL, USA). The tumor 
volume was further estimated by measuring the length and the width of the tumor leg with a 
caliper, and the volume was calculated according to the formula V= length x width
2
/2.  The 
volume of the non-injected leg was used as a reference value. The mice were sacrificed in 
week 12 after tumor cell injection and the lung was perfused in situ as described.
(25)
   Primary 
tumors and lungs were fixed at RT in 2% formaldehyde for 30 minutes and processed for X-
gal staining as reported.
(27)
 Indigo-blue stained metastases on the surface of lung whole 
mounts were counted at 4x magnification under the Nicon Eclipse E600 microscope (Nikon 
Corporation, Tokio, Japan)  equipped with an integrated size grid. Metastatic foci smaller than 
0.1 mm in diameter were considered as micrometastases and foci bigger than 0.1 mm as 
macrometastases. Two independent animal experiments were performed and the data were 
pooled.  
Statistical analysis  
Overall and event-free patient survival was calculated using Kaplan–Meier curves and 
statistical significance was assessed with the log-rank test. Differences between means were 
analyzed by the Student t-test and p < 0.05 was considered significant. The results are 
presented as means ± standard errors of the mean (SEM).  
Results 
CD44 expression in human OS tumor samples is an additional prognostic factor 
in non-responders and in patients with lung metastases 
Human OS tissue-microarray sections including tumor specimens from 53 patients were 
analyzed immunohistochemically for total CD44 expression (Fig. 1). The adequacy of our 
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patient cohort was evaluated by determining the correlation of chemotherapy response and the 
presence of metastases with the overall survival, as these were identified as key determinants 
of prognosis in OS.
(29)
 Indeed, non-responders and metastases-positive patients had 
significantly shorter overall survival (p < 0.05, p < 0.0001, respectively) than responders and 
metastases-free patients (not shown). Patients poorly responding to chemotherapy developed 
lung metastases more rapidly, and had a mean event-free survival of 14 ± 2 months compared 
to 40 ± 2 months in patients with good response (p < 0.05; Fig. 1B). A Kaplan-Meier analysis 
revealed a tendency of shorter overall mean survival (50 ± 8 months) of patients with positive 
CD44 staining in tumor resections than patients with undetectable CD44 staining (88 ± 8 
months; p = 0.0758; Fig. 1C). Non-responders that were CD44 positive had a tendency of 
shorter overall survival than CD44 negative patients (p = 0.0732; Fig. 1D). In addition, non-
responders with CD44 positive staining in their tumor samples had significantly shorter mean 
event-free survival of only 8.3 ± 1.4 months than patients with undetectable CD44 in tumor 
sections with mean event-free survival of 16.5 ± 3 months (p < 0.05; Fig. 1E). Strikingly, all 
patients that were positive for both CD44 expression and metastases died within 22 months 
significantly earlier than CD44 negative patients (p < 0.0001; Fig. 1F). The findings implicate 
that CD44 is an additional negative predictor for OS patients’ outcome, in addition to the 
commonly used prognostic parameters such as chemotherapy response and presence of 
metastases. 
Overexpression of CD44 in an osteoblastic OS cell line increases the adhesion to 
HA, promotes cell migration and induces chemoresistance  
Based on the tissue microarray results, we hypothesized that CD44 may have a significant 
impact on the metastatic activity and the chemoresistance of OS cells. We therefore 
overexpressed by retroviral gene transfer the C-terminally V5/His6-tagged standard isoform 
CD44s in the human low metastatic SaOS-2 OS cell line with low endogenous CD44 
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expression. The standard isoform, with all the variant exons excised, was chosen for 
overexpression because it was found expressed as the predominant isoform in other human 
OS cell lines (not shown). The V5/His6-tagged HA binding-defective mutant CD44s R41A 
was included in the study to assess the relevance of CD44/HA interactions in the regulation of 
the metastatic ability and chemoresistance of SaOS-2 tumor cells. Western blot analysis of 
whole cell extracts with a pan-CD44 antibody (Hermes3) indicated overexpression of CD44s 
and CD44s R41A in respective SaOS-2 CD44s and SaOS-2 CD44s R41A cells compared to 
control SaOS-2 EV (Fig. 2A). The protein components detected by Hermes3 and V5 
antibodies had the expected size of approximately 100 kDa. 
A significant (p < 0.01) 4.2-fold higher percentage of HA-adhering SaOS-2 CD44s cells 
compared to SaOS-2 EV cells in an assay examining short-term (30 minutes) adhesion 
demonstrated the functional expression of CD44s at the cell surface (Fig. 2B). Consistent with 
the binding defect of CD44s R41A, the adhesion of SaOS-2 CD44s R41A cells to HA was 
indistinguishable from that of SaOS-2 EV cells. A significant reduction in the percentage of 
short-term adhering SaOS-2 CD44s cells by preincubation with Hermes1 CD44s blocking 
antibodies, which was not observed with control IgG, further confirmed that increased 
adhesion of SaOS-2 CD44s cells to HA was indeed mediated by direct interaction of 
overexpressed CD44s at the cell surface with HA (Fig. 2C). Interestingly, pretreatment of 
SaOS-2 CD44s cells with Hermes1 antibodies inhibited their adhesion to HA to a percentage 
comparable to that of control SaOS-2 EV cells, indicating that CD44s blocking was almost 
complete. It is also important to note that pretreatment of SaOS-2 EV and of SaOS-2 CD44s 
R41A cells with Hermes1 did not affect short-term adhesion of the two cell lines to HA (not 
shown). 
Tumor cell migration, another indicator of metastatic potential in vitro, was investigated with 
the CD44s expression-manipulated cells in a transwell migration assay. The migration rates of 
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SaOS-2 CD44s and SaOS-2 CD44s R41A cells were 4-fold (p < 0.05) and 3-fold (p < 0.05) 
higher than that of SaOS-2 EV cells (Fig. 2D) suggesting that the CD44s expression-related 
increase in migration activity was not dependent on CD44s/HA interactions. On the other 
hand, effects of CD44s overexpression on the proliferation of SaOS-2 cells was not observed. 
The calculated doubling times were 38.2 ± 1.6h for SaOS-2 EV cells, 42.1 ± 4.7h for SaOS-2 
CD44s and 46.7 ± 5.2h for SaOS-2 CD44s R41A cells (Fig. 2E). Thus, overexpression of 
CD44s in SaOS-2 cells enhanced the in vitro metastatic properties such as adhesion and 
migration in HA-dependent and HA-independent manner, respectively, without affecting cell 
proliferation. 
The tissue microarray analysis of OS resections also suggested that expression of CD44 in 
primary tumor tissue is related to and may even directly enhance the resistance to commonly 
used chemotherapeutics in OS patients. The here presented results of cytotoxicity experiments 
with CD44s and CD44s R41A overexpressing and control SaOS-2 EV cells supported this 
hypothesis. The half-maximal growth inhibitory concentration (IC50) of cisplatin was 2.4-fold 
higher (p < 0.01) in SaOS-2 CD44s cells than in control SaOS-2 EV cells (Fig. 2F). This 
significant increase in chemoresistance was not observed with the HA binding-defective 
CD44s R41A mutant implying that increased cisplatin resistance was only partially HA-
dependent.  A tendency of increased chemoresistance of SaOS-2 CD44s cells to doxorubicin 
and etoposide was also found (not shown). 
CD44s enhances intratibial primary tumor growth and pulmonary metastasis in a 
xenograft OS mouse model in a HA-dependent manner 
The in vitro experiments showed that CD44s, when overexpressed in SaOS-2 cells, enhances 
adhesion and migration, cellular processes essential for the metastatic progression. We 
therefore compared the growth and metastasis of SaOS-2 EV, SaOS-2 CD44s, SaOS-2 CD44s 
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R41A cell line-derived intratibial primary tumors in SCID mice. Osteoblastic lesions were 
first observed by X-Ray in mice that were injected with SaOS-2 CD44s cells 50 days after 
tumor cell injection (Fig. 3A). SaOS-2 EV and CD44s R41A cell-derived tumors developed 
more slowly and the first osteoblastic lesions became visible 2 weeks after those in mice 
injected with SaOS-2 CD44s cells. At the end of the experiment on day 90 after tumor cell 
injection, SaOS-2 CD44s cell-derived tumors showed more extensive bone structures on X-
ray images than tumors of SaOS-2 EV and SaOS-2 CD44s R41A cells. The animals became 
moribund in the 12
th
 week after tumor cell injection and were subsequently sacrificed. Finally, 
CD44s-xenografts with a mean primary tumor volume of 226 ± 29 mm
3
 were significantly (p 
< 0.05) larger than SaOS-2 EV (121 ± 25 mm
3
) and SaOS-2 CD44s R41A (130 ± 31 mm
3
) 
xenografts (Fig. 3B). Moreover, the ex-vivo analysis of whole mounts of lungs revealed 2.5 
and 2.2 times higher numbers of X-gal-stained macrometastases in SaOS-2 CD44s than in 
SaOS-2 EV and SaOS-2 CD44s R41A tumor bearing mice, respectively (p < 0.01; Fig. 4B).  
Similarly, the  mean number of micrometastases was 2- and 2.2 times higher on the lungs of 
mice with SaOS-2 CD44s cell-derived tumors than on the respective lungs dissected from 
SaOS-2 EV and SaOS-2 CD44s R41A tumor bearing animals (p < 0.05; Fig. 4C). The 
significant differences in tumor size and in the mean number of lung macro- and 
micrometastases in SaOS-2 CD44s compared to SaOS-2 CD44s R41A tumor bearing mice 
clearly indicated that the observed CD44s-promoted enhanced malignancy of SaOS-2 CD44s 
cells was dependent on interaction with HA. 
Discussion 
Osteosarcoma is the second leading cause of cancer-related death in pediatric age group and 
young adults.
(30)
 This high mortality is due to development of pulmonary metastases that are 
detectable already in 15-20% of the patients at the time of diagnosis. In order to devise 
successful disease management strategies and to improve the survival rate of OS patients, it is 
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essential to gain a profound understanding of OS and metastasis progression as well as 
associated chemoresistance mechanisms. Identification of novel OS molecular markers that 
will serve as therapeutic targets is crucial for the design of effective treatment of this 
devastating disease. 
In the present study, we investigated the prognostic value of CD44 expression for OS 
patients’ outcome, as well as the biological relevance of CD44-HA interactions in an 
orthotopic xenograft OS mouse model. In our tissue microarray analysis, we evaluated the 
predictive value of total CD44 protein expression. CD44s is probably the main isoform 
expressed in OS samples, as it is the predominant isoform expressed in several established OS 
cells lines (not shown) that are of mesenchymal origin. This is in line with a study conducted 
by Brown et al. where the authors demonstrate that a switch in expression from CD44 variant 
isoforms to CD44s is essential for epithelial-mesenchymal transition and that mesenchymal 
CD44s is upregulated in advanced human breast carcinomas.
(31)
 On the other hand, our 
suggestion is in contrast with two studies that found variant CD44 isoforms to be correlated 
with poor survival of OS patients.
(18,19)
 We did not find a significant correlation between 
CD44 expression and overall survival, which is in good agreement with recent reports of 
Boldrini et al. and Xu-Dong et al.
(20,32)
 Interestingly, Xu-Dong et al. observed that OS patients 
with high expression of CD44 gene were more prone to have metastases.
(32)
 Our Kaplan-
Meier analysis, however, revealed a significant correlation between CD44 expression in OS 
surgical tumor specimens of patients with a poor response to preoperative chemotherapy and 
shorter event-free survival. Moreover, CD44 positive patients with metastasis had a 
significantly shorter overall survival when compared to CD44 negative patients with 
metastatic disease. Despite the limited number of patient samples analyzed due to the low 
incidence of OS, our data indicate that CD44 expression is an additional prognostic indicator 
together with chemotherapy response and metastasis presence that are commonly employed in 
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the clinics as parameters for predicting clinical outcomes among OS patients.
(7)
 In the 
emerging era of personalized oncology care, the ultimate goal is to tailor therapy to individual 
patients according to distinct characteristics of their tumors in order to enhance clinical 
efficiency while minimizing the adverse toxic side effects of antineoplastic drugs.
(33)
 We 
suggest CD44 as a molecular marker that can be used to identify subgroups of patients with 
different prognosis and that can further be a basis for individualized treatment. Stratification 
of patients into different-risk categories may guide the choice of postoperative chemotherapy. 
Our findings identify CD44 positive patients within non-responders and patients with 
metastatic disease as high-risk patients that, therefore, may be considered as candidates for 
intensified chemotherapy or novel therapeutic strategies.  
Based on our tissue microarray analysis, we speculated that CD44 may be an important player 
in the metastatic behavior and chemoresistance of OS cells. In fact, making use of a xenograft 
orthotopic mouse model of OS, we demonstrated that CD44s has a tumor- and metastatic-
promoting activity upon overexpression in a human osteoblastic SaOS-2 cell line. The 
malignancy enhancing effect of CD44s was HA-dependent and was reflected in the 
significant increase of primary tumor volume and the numbers of pulmonary micro- and 
macrometastases when compared to that of SaOS-2 EV  and SaOS-2 CD44s R41A cells. 
Apparently, CD44s affected both dissemination of tumor cells and their growth re-
establishment at the secondary site. In vitro experiments showed that overexpression of 
CD44s promotes adhesion to HA and facilitated migration of SaOS-2 cells. The observed 
increase in migration rates upon overexpression of CD44s did not rely on the binding capacity 
to HA. This observation is not surprising given the fact that CD44 also functions as a co-
receptor of several receptor tyrosine kinases, such as c-Met and members of ERBB receptor 
family, and can thereby modulate the signaling of associated growth factor receptors.
(10)
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We did not observe any effects of CD44 overexpression on proliferation in vitro as opposed to 
the in vivo experiments where CD44s overexpressing cells formed bigger tumors in 
comparison to EV and CD44s R41A cells upon intratibial injection. These findings once 
again show that in vitro conditions do not fully replicate the physiological situation and 
highlight the major impact of tumor microenvironment on tumor development, which is 
already well established. Furthermore, additionally to promoting migration, CD44s induced in 
vitro chemoresistance of SaOS-2 cells to cisplatin which is in good agreement with our tissue 
microarray results. The CD44s effect on response to this cytotoxic drug appeared to be only 
partially dependent on HA binding ability which implicates involvement of additional 
mechanisms. In the past years, several lines of evidence indicated that HA and CD44 promote 
chemoresistance in a wide spectrum of tumor cell types, including breast, lung, head and neck 
carcinomas and lymphoma.
(34)
 It was shown that CD44/HA interaction regulates drug 
transporter expression in breast carcinoma cells.
(17)
 CD44 is associated with multidrug 
transporters in malignant peripheral nerve sheath tumor cells, and disruption of CD44/HA 
interactions abrogated drug resistance in these cells.
(35)
 Recently,  Xu et al. reported evidence 
that CD44 attenuates the activation of the Hippo signaling pathway and consequently 
promotes resistance of glioma cells to cytotoxic-agent induced stress.
(16)
   At this point, it is 
important to notice that in numerous types of human carcinomas CD44 is a common marker 
for cancer stem cells (CSC), that are highly resistant to chemotherapy.
(15)
 The underlying 
mechanism of CD44 induced chemoresistance in OS still remains to be elucidated. The future 
research should be directed towards confirming CD44 induced chemoresistance in animal 
models of OS.  
In summary, our study identified CD44 as an additional negative predictor for OS patients’ 
outcome that enables stratification of patients into subgroups which may lead to more 
efficient personalized therapy. With the SaOS-2 model we developed a system that allows 
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investigating the relevance of individual CD44 isoforms for the tumor biology of osteoblastic 
OS in a cellular background of insignificant endogenous CD44 expression. Findings 
presented here underscore the important role of CD44s/HA interaction in determining tumor 
malignancy in experimental OS. Taken together, our results point to CD44/HA interaction as 
a promising target for therapeutic intervention in OS. 
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Figure legends 
Fig. 1. Kaplan-Meier analyses of osteosarcoma tissue microarray immunostained with pan-
CD44 antibodies. (A) Representative images of tumor tissue microarray sections showing 
non-detectable (left), moderate (middle) and intense (right) CD44 immunostaining. (B) 
Event-free survival of responders (Salzer-Kuntschik et al. (  ), grade I-III) or of non-
responders (grade IV-VI) to neoadjuvant chemotherapy. (C) Overall survival of patients with 
non-detectable (CD44 neg) or with moderate or intense (CD44 pos) immunostaining of tumor 
tissue. Overall (D) and event-free (E) survival of non-responders to neoadjuvant therapy with 
CD44 neg or CD44 pos tumors. (F) Overall survival of patients with metastases and CD44 
neg or CD44 pos tumors.  
Fig. 2. Overexpression of CD44s in SaOS-  cells increases the adhesion to HA, promotes cell 
migration and enhances cisplatin chemoresistance, but does not affect proliferation. (A)  
SaOS-  cells were retrovirally transduced with empty vector (EV) or with constructs 
encoding CD44s or HA binding-defective CD44s R41A, and the expression of respective 
proteins was confirmed on Western blots of cell extracts analyzed with CD44 antibody 
Hermes  (H ), V5 antibody and antibody to GAPDH (protein loading control). (B) Adhesion 
(  of seeded cells) to immobilized hyaluronan within  0 min of EV-transduced or of CD44s 
- or CD44s R41A expressing cells. (C) Adhesion (  of seeded cells) of CD44s expressing 
cells to hyaluronan in the absence (-H1) or in the presence (+H1) of the CD44-blocking 
Hermes1 antibody or of control IgG. Transwell migration (  of seeded cells) (D), 
proliferation (E) of EV-transduced or of CD44s or CD44s R41A expressing cells and 
cisplatin cytotoxicity (F) in respective cell lines determined in a WST-1 assay. IC
50
, half-
maximal growth inhibitory concentrations of cisplatin. Values in (B) - (F) are expressed as 
means ± SEM of at least three independent experiments; *, p < 0.05. 
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Fig. 3. Overexpression of CD44s in SaOS-  cells enhances intratibial osteoblastic primary 
tumor growth in SCID mice in a HA-dependent manner. (A) Representative X-ray images of 
tumor-bearing legs taken on indicated days after intratibial injection of cells transduced with 
empty vector (EV) (11 mice) or cells expressing CD44s (8 mice) or CD44s R41A (9 mice). 
(B) Mean (± SEM) primary tumor volume in respective mice 1  weeks after tumor cell 
injection. *, p < 0.05. 
 Fig. 4. CD44s overexpression in SaOS-  cells enhances pulmonary metastasis of intratibial 
primary tumors in a HA-dependent manner in SCID mice. (A) Representative images of blue 
X-gal stained metastatic nodules in the lungs of mice bearing tumors derived from empty 
vector (EV)-transduced or CD44s - or CD44s R41A expressing cells. Bars,  50  m. 
Quantification of pulmonary macrometastases (B) and micrometastases (C) on lung whole 
mounts prepared after sacrifice in week 1  after tumor cell injection. Values are the mean ± 
SEM; *, p < 0.05. 
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n=53 % 
Gender 
  Male 34 64 
Female 19 36 
   Age 
  <10 10 19 
10 to 19 26 49 
20 to 29 11 21 
30 to 39 2 4 
40 to 49 2 4 
50 to 59 2 4 
   Tumor type 
  Osteoblastic 38 72 
Chondroblastic 7 13 
Fibroblastic 4 8 
Teleangiectatic 4 8 
   Anatomic site 
  Extremities 46 87 
Spine and pelvis 6 11 
Face 1 2 
   
   Chemotherapy response 
  Responders (S-K-I-III) 30 57 
Non-responders (S-K-IV-VI) 23 43 
Salzer-Kuntschik I 6 11 
Salzer-Kuntschik II 13 25 
Salzer-Kuntschik III 11 21 
Salzer-Kuntschik IV 11 21 
Salzer-Kuntschik V 9 17 
Salzer-Kuntschik VI 3 6 
   Metastasis 
  No metastasis 34 64 
Total metastasis 19 36 
Metastasis at diagnosis 2 4 
Metastasis after diagnosis 17 32 
Table 1: Clinical characteristics of osteosarcoma patients 
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Supplemental data 
Table 1. Tissue microarray grading method 
 0 – 10 % staining 11 – 50 % staining 51 – 100 % staining 
Weak staining 1 1 1 
Moderate staining 1 2 2 
Strong staining 1 2 3 
 
Fig. 1. Example of positive staining area percentage calculation 
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Abstract 
Osteosarcoma (OS) is the most common primary malignant bone cancer in children and 
adolescents with a high propensity for lung metastasis. Therefore, it is of great importance to 
identify molecular markers leading to increased metastatic potential in order to devise more 
effective therapeutic strategies that suppress metastasis, the major cause of death in OS. 
CD44, the principal receptor for the extracellular matrix component hyaluronan (HA), is 
frequently found overexpressed in tumour cells and has been implicated in metastatic spread 
in various cancer types. Here, we investigated the effects of stable shRNA-mediated CD44 
down-regulation on in vitro and in vivo metastatic properties of the highly metastatic human 
143-B OS cell line. In vitro, CD44 knockdown resulted in a 73 % decrease in the adhesion to 
HA, a 57 % decrease in the migration rate in a trans-filter migration assay, and a 28 % 
decrease in the cells’ capacity for anchorage-independent growth in soft agar, implicating that 
CD44 expression contributes the metastatic activity of 143-B cells. However, making use of 
an orthotopic xenograft OS mouse model, we demonstrated that reduced CD44 expression 
facilitated primary tumor growth and formation of pulmonary metastasis. The enhanced 
malignant phenotype was associated with decreased adhesion to HA and reduced expression 
of the tumor suppressor merlin in vivo. In conclusion, our study identified CD44 as a 
metastasis suppressor in this particular experimental OS.  
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Introduction 
Osteosarcoma (OS) is the most common primary malignant bone cancer in children and 
adolescents, characterized by the presence of spindle-like tumor cells which produce 
immature bone or osteoid. The overall incidence is three patients/million/year with the median 
peak at the age of 16 [1]. OS has a high propensity for metastasis to the lung and bones and 
already 20% of patients have detectable metastases at the time of diagnosis, while 80% of 
patients who initially present with localized disease subsequently develop metastases [2,3].  
Significant clinical improvements over the past several decades through the use of 
combination chemotherapy and surgery have led to a dramatic increase in the survival of 
patients with localized disease. However, patients with metastatic or recurrent disease 
continue to have a very poor prognosis, with <20% long term survival [3] . Therefore, it is of 
great importance to elucidate the molecular mechanisms leading to increased metastatic 
potential. Understanding the basic biology of OS progression will enable us to devise novel 
strategies for treatment that suppress metastasis, the major cause of death in OS, and that will 
finally improve the survival of these patients.  
CD44 has been described to be associated with increased metastatic spread in different 
types of cancer [4]. It is a cell-cell and cell-matrix adhesion molecule and the principal 
receptor for hyaluronan (HA), a major component of the extracellular matrix [5]. CD44 is a 
polymorphic transmembrane glycoprotein with various biological functions in development, 
inflammation, haematopoiesis, wound healing, immune response and tumor progression [6].  
The wide range of CD44 activities is mainly due to post-translational modifications and the 
existence of multiple isoforms, generated by the insertion of variable regions in the 
extracellular domain through alternative splicing [7]. Over the last decade, numerous 
publications have addressed the relevance of CD44 isoforms as prognostic factors for human 
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cancers. It appears that the CD44 expression and the occurrence of metastasis are directly or 
inversely related depending on the organ of origin and the pattern of CD44 isoforms 
expression. Studies have shown up-regulated expression of CD44 variants in many human 
tumors, including gastric cancer, pancreatic cancer, lung and renal cell cancer. [8,9,10,11]. 
Several reports point to the importance of the standard form of CD44 (CD44s), without the 
variant exons, in the tumor progression [12]. However, in other tumor types, namely 
neuroblastoma and prostate cancer, the lack of CD44 expression (both the standard and the 
splice variants) correlates with poor prognosis [13,14]. CD44 even acts as a metastasis-
suppressor gene in prostate carcinoma cells [6,15].    
Little is known about the contribution of CD44 to OS progression and metastasis. Two 
immunohistochemical studies of osteosarcoma tissue specimens came to different 
conclusions. Kim et al. reported that overexpression of CD44v5 correlated significantly with 
metastasis and lower survival rates [16]. On the other hand, in the tumor samples analyzed by 
Kuryu et al. a correlation between the overexpression of CD44 isoforms containing variant v6 
and poor prognosis was found [17]. In both studies total CD44 expression was not correlated 
with prognosis.  
Few studies with established OS cell lines indicated the relevance of HA in tumor 
progression. Hosono et al. showed the tumorigenicity of the OS cell lines MG63 and LM8 in 
vitro and in vivo was inhibited by HA oligosaccharides via perturbation of HA-rich 
pericellular matrix of the cells [18]. Study performed by Nishida et al. showed an inhibition of 
HA retention and tumorigenicity of MG63 OS cells upon antisense inhibition of HA synthase 
(HAS)-2 [19]. HAS-3 derived HA enhanced OS cell activities required for metastasis, such as 
proliferation, invasion, and degradation of extracellular matrix [20]. 
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In the present work, we investigated the effects of CD44 down-regulation in a highly 
metastatic osteosarcoma cell line 143-B on its’ metastatic behavior in vitro as well as the 
effects on tumor growth and metastasis formation in vivo in a xenograft orthotopic mouse 
model of osteosarcoma. 
Materials and Methods 
Cell culture and transduction  
143-B (CRL-8303) cells were obtained from American Type Culture Collection (ATCC, 
Rockville, MD). The cells were cultured in DMEM (4.5 g/l glucose)/HamF12 (1:1) medium 
(Invitrogen; Carlsbad, CA) supplemented with 10% heat-inactivated FCS (GIBCO, Basel, 
Switzerland). Cells were cultured at  7  C in a humidified atmosphere of 5  CO2/95% air. 
143-B cells stably overexpressing LacZ gene (Husmann et al., submitted) were used for stable 
knockdown of CD44 using a retroviral approach. Specific shRNA against CD44 (shCD44) 
and a non-targeting control shRNA (Ctrl shRNA) in pSirenRetroQ vector (Clontech; Paolo 
Alto, CA) were kindly provided by Prof. Ivan Stamenkovic (Lausanne, Switzerland) [21]. 
Retroviral particles containing shCD44, Ctrl shRNA and pSirenRetroQ empty vector (EV) 
were produced in HEK293-T cells according to a modified protocol of Mitta et al. as 
described in Arlt et al. [22]. 143-B/LacZ cells were infected by 48h incubation with virus-
containing medium supplemented with 8 µg/ml polybrene. Cells were subsequently 
maintained in cell culture medium containing 2 µg/ml puromycin (Invitrogen). Selection 
revealed 143-B EV, 143-B shCD44 and 143-B Ctrl shRNA. Prior to animal experiments the 
population of cells with silenced CD44 was enriched by incubation on HA coated plates (100 
µg/cm
2
; Sigma Aldrich, St. Luis, MO) for 10 min at  7  C. Supernatant containing the non-
adhered cells was collected. 
Immunocytochemistry  
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Cells were allowed to grow to subconfluency on glass microscope cover slips in 24-well 
plates. After washing with PBS, the cells were fixed in 4% formalin in PBS for 20 min at 
room temperature (RT). DMEM/F12 (1:1) containing 0.1% BSA was used for blocking for 30 
min at RT. Cells were then incubated with the primary pan anti CD44 antibody (Hermes3;  2 
µg/ml in blocking medium, a kind gift from Dr. S. Jalkanen, Turku, Finland) for 2h at RT. 
After extensive washing secondary anti-mouse antibody (Alexa Fluor 546; Invitrogen) at a 
final dilution 1:200 was added to the cells and incubated for 30 min in the dark. The 
coverslips were washed with PBS, dipped in H2O, mounted in Immomount 
(ThermoScientific; Waltham, MA) and examined by fluorescence microscopy using the Zeiss 
Observer.Z1 inverted microscope equipped with an appropriate filter block (Ziess 43) (Carl 
Zeiss MicroImaging GmbH, Göttingen, Germany).  
Western blot analysis  
Cells were lysed on a carrousel at 4  C in lysis buffer containing 50 mM Tris HCl (pH 7.5), 
150 mM NaCl, 1% NP40, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulfate (SDS), 1 mM 
dithiothreitol (DTT), 1 mM phenylmethylsulphonyl fluoride (PMSF) and 10 mg/ml aprotinin. 
The cellular debris was removed by centrifugation at 13000 rpm, 4  C for  0 min. E ual 
amounts of proteins were separated by 8% SDS-PAGE. Following electrophoresis gels were 
blotted onto Hybond-ECL membranes (GE Healthcare, UK). For detection of CD44 and 
GAPDH mouse monoclonal antibody Hermes3 at concentration 1 µg/ml, and rabbit 
polyclonal anti-GAPDH (Santa Cruz Biotechnologies, CA; 1:3000) antibodies were used. 
HRP-conjugated secondary antibodies were purchased at Santa Cruz Biotechnologies. The 
peroxidase-conjugated antibodies were visualized by chemoluminescence with the Immobilon 
chemoluminescence substrate (Millipore, Billerica, MA) using the VersaDoc
TM 
Imaging 
System (Bio-Rad; Hercules, CA). 
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Adhesion assay  
Adhesion assay was performed in 96-well plates coated with 333 µg/cm
2 
of high molecular 
weight HA (HMW-HA; Sigma-Aldrich) over night at 4  C, washed with PBS and blocked 
with heat-denatured (HD) 1% BSA. Non-coated wells or wells coated only with HD-BSA 
were used as controls. Subconfluent cells were detached with accutase (Sigma-Aldrich) and 
10
4
 cells per well were seeded in triplicates and allowed to adhere for  0 min at  7  C. Non-
adherent cells were removed by washing and adherent cells were subsequently fixed with 
10% formalin in PBS for 15 min at RT and stained with 0.05% crystal violet in H2O for 15 
min at RT. Photos were taken with the AxioCam MRm camera connected to the Zeiss 
Observer.Z1 inverted microscope at 4x magnification corresponding to an area of 3.6 mm
2
 
and the number of adherent cells was determined by ImageJ software. The total number of 
adherent cells per well was calculated and the percentage of adherent cells was obtained by 
dividing the number of adherent cells with the total number of seeded cells and multiplying 
with 100. The calculated percentage of adherent EV cells was set as 100% and the results are 
presented in relation to EV cells. The experiments were repeated three times. 
Migration assay  
The transwell migration assay was conducted as reported recently [22]. Briefly, 5-10 x 10
3
 
cells were allowed to migrate through cell culture inserts (Becton Dickinson, San Jose, CA) 
with 8 µm porous filters in 24-well plates for 6h at 7  C. After incubation non-migrated cells 
on the upper side of the insert were removed by wiping with a cotton swab. Migrated cells on 
the lower side of the filters were fixed with 10% formalin, permeabilised with 50 µM 
digitonin (Calbiochem; Switzerland) and stained with 300 nM Picogreen in PBS (Invitrogen; 
1:200) for 15 min at RT. Three pictures per insert (two inserts per cell line) were taken the 
AxioCam MRm camera connected to the Zeiss Observer.Z1 inverted microscope equipped 
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with an appropriate filter block for blue excitation at a 10x magnification corresponding to an 
area of 0.58 mm
2
. The number of cells that migrated to the lower side of the polycarbonate 
filters was determined using the ImageJ software, and the results are presented as described 
for the adhesion assay. The experiments were performed at least three times. 
In vitro cell proliferation assay  
Subconfluent cells in the logarithmic growth phase were trypsinized and 5 x 10
4
 cells were 
seeded in triplicates in 12.5 cm
2
 flasks in 2.5 ml of cell culture medium and allowed to grow 
for 1 to 5 days. Cells were detached by trypsin every 24h and cell number was determined by 
counting in the Neubauer chamber. The equation N=No e
kt
 was used to calculate the doubling 
time during logarithmic growth  
Soft agar colony formation assay  
To form the bottom agar layer 1.5 ml of 0.5% DNA grade agarose (Promega, Madison, 
WI) in cell culture medium were added per well in 6-well plates. The plates were kept at 4  C 
before use. 2 x 10
4
 cells were mixed in 1.5 ml of 0.35% agarose in cell culture medium and 
added on top of the bottom agar layer. After 24h at  7  C   ml per well of cell culture medium 
with PSA was added. The medium was replaced every   days and the cells were cultured for 
14 days. Colonies were stained with   ml 0.005  crystal violet overnight at 4  C. Three photos 
per well were taken with the AxioCam MRm camera connected to the Zeiss Observer.Z1 
inverted microscope at 4x magnification. ImageJ software was used for determining the 
number and size distribution of colonies. The number of colonies formed by EV cells was set 
as 100%. The experiments were repeated four times in triplicates. 
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Intratibial xenograft mouse OS model   
SCID/CB17 immunocompromised mice were obtained from Charles River Laboratories 
(Sulzfeld, Germany) at the age of 8 weeks, at least 14 days before the start of the experiment. 
The animal experiments were approved by the authorities of Kanton Zürich and were 
conducted in accordance with the guidelines of the “Schweizer Bundesamt für 
Veterinärwesen”. On day 0 of the experiment   x 105 of 143-B cells (engineered as described) 
in 10 µl of PBS/0.05% EDTA containing Matrigel (Becton-Dickinson; Franklin Lake, NJ) 
were injected intratibially. Following the injection, mice health condition was closely 
monitored. The tumor length and width were measured with a caliper and the X-ray detection 
of osteolytic lesions was performed with MX-20 DC Digital Radiography System (Faxitron 
X-Ray Corporation, Lincolnshire, IL) once per week. Tumor volume was calculated 
according to the formula V= length x width
2
/2. The mice were sacrificed 21 days after tumor 
cell injection and in situ lung perfusion was conducted as described [22]. As the cells used 
expressed LacZ gene, visualization of tumor cells within mouse tissue was facilitated. Organs 
were fixed in 2% formaldehyde for 30 min at RT, washed three times with PBS and incubated 
in 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal) staining solution for at least 3 hours 
as described [23,24]. The indigo-blue stained metastases on the lung surface were counted 
under the microscope. The animal experiments were carried out three times. Representative 
experiment is shown. 
Immunohistochemistry  
Tumors and lungs previously fixed in 4 % formaldehyde were dehydrated through 70%, 
96%, 100% ethanol and xylene and then embedded in paraffin (Applied Biosystems, Foster 
City, CA). Sections (6 µm) were cut and mounted onto slides. The sections were then 
deparaffinized and rehydrated and the antigen retrieval was performed by heating in 0.1 M 
citrate buffer (pH 5.8). The endogenous peroxidase was blocked by incubation with 3% H2O2 
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for 10 min atRT. The unspecific binding was blocked by incubation with 10% goat serum 
(Vector Laboratories; Burligame, CA) containing 0.1% Tween (Sigma Aldrich) in Tris 
buffered saline (TBS;  50 mM Tris, 150 mM NaCl, pH 7.4) for 1h at RT. Primary antibodies 
anti-CD44 Hermes3 (2 µg/ml, diluted in blocking solution), anti-merlin NF2 (Santa Cruz 
Biotechnologies; 4µg/ml) and anti-Ki67 (Abcam; Cambridge, UK; 4 µg/ml) were then 
applied to the slides for 1h at RT. After washing with TBS, secondary biotinylated goat anti-
mouse IgG antibody (Vector; 1:200) was applied to the sections for 1h at RT. Omission of 
primary antibody served as negative control. After washing with TBS, the sections were 
incubated with avidin-biotin peroxidase (ABC kit; Vector Laboratories) and again washed 
with TBS. The color was developed with AEC (Dako; Carpinteria, CA). Finally, the slides 
were briefly counterstained with hematoxylin. Recombinant mouse CD44 Fc chimera (100 
µg/ml; R&D Systems, Minneapolis, MN) was used for detection of hyaluronan in tissue 
sections with the standard protocol, excluding the antigen retrieval step. As negative controls 
we incubated the slides with hyaluronidase (200 U/ml; Sigma Aldrich) overnight at 37  C prior 
to staining or we preincubated CD44 Fc chimera with hyaluronan (1 mg/ml; Sigma Aldrich) 
before applying it to slides. 
Statistical analysis  
Differences between means were analyzed by the Student t-test and p<0.05 was considered 
significant. The results are presented as means ± SEM.  
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Results 
CD44 down-regulation in the highly metastatic 143-B OS cell line  
In order to study CD44 involvement in the malignant phenotype of 143-B OS cells, we 
stably knocked-down CD44 in 143-B cell using shRNA through retroviral transfer approach 
as described in Materials and Methods section. Western blot analysis of whole cell lysates 
demonstrated almost abolished total CD44 expression in 143-B shCD44 cells (Fig. 1A). 
The cell surface expression assessed by immunocytochemistry in non-permeabilized cells 
showed CD44 depletion in cells infected with the CD44 specific shRNA (shCD44), whereas 
cells infected with the control shRNA (Ctrl shRNA) and the empty vector (EV) displayed 
high levels of membrane-bound CD44 (Fig. 1B).  
CD44 silencing inhibits adhesion to hyaluronan and cell migration 
Next we investigated whether CD44 down-regulation modulates the cells’ ability to bind to 
HA, the major ligand of CD44. CD44 knock-down resulted in a 73±7.5% (p<0.02) decrease 
in the adhesion to HA compared to the EV cells. Cells transduced with the Ctrl shRNA 
showed unaltered adhesion in comparison to EV cells (Fig. 2A).  
In order to determine whether CD44 silencing might influence migration capacities of 143-
B cells we performed a trans-filter migration assay. We observed a 57±4.2% (p<0.0001) 
decrease in migration in cells with down-regulated CD44 in comparison to the EV cells. In 
contrast, Ctrl shRNA did not have an impact on the migration rate (Fig. 2B). 
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CD44 silencing has no effect on in vitro growth of adherent cells, but reduces 
anchorage-independent growth 
We examined the potential effect of stable CD44 down-regulation on anchorage-dependent 
and anchorage-independent cell growth. There was no significant difference in the 
proliferation on plastic of adherent cells in tissue culture flasks between the cells with 
manipulated CD44 expression and the control cells, with the calculated doubling times being 
19.1±0.6 h for EV cells, 19.9±1.3 h for shCD44 cells and 20.0±0.9 h for Ctrl shRNA cells 
(Fig. 2C). However, when we assessed the anchorage-independent growth in a soft agar 
colony formation assay, a 28±6% (p<0.02) reduction in the total colony number formed by 
shCD44 cells compared to control cells was found (Fig. 2D). The colony size was comparable 
between the cell lines (not shown).  
Reduced CD44 expression facilitates primary tumor growth and lung metastases 
formation in a xenograft OS mouse model 
The in vitro experiments point to important roles of CD44 in several cellular processes 
contributing to the metastatic activity of 143-B cells. Therefore, we studied how CD44 down-
regulation affects primary tumor growth and metastases progression in a mouse model. 143-B 
cells with suppressed CD44, EV or non-targeting Ctrl shRNA were injected intratibially into 
SCID/CB17 mice. Osteolytic lesions, that are a characteristic feature for 143-B cells, could be 
detected by X-ray starting at day 14 after tumor cell injection in all three groups of 
experimental animals. No dramatic differences in the extent of osteolysis between the groups 
were found (Fig. 3A). However, CD44 knock-down significantly increased the mean final 
primary tumor volume (108±14 mm
3
, n=9) in comparison with the group of mice injected 
with cells carrying only the EV (39±6 mm
3
, n=9; p<0.001). 143-B Ctrl shRNA cells upon 
injection into mice gave rise to tumors with the mean final volume of 65±25 mm
3
 (n=6; Fig. 
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3B). The difference in tumor volume between shCD44 xenografts and Ctrl shRNA xenografts 
did not reach significance, most probably due to the fact that Ctrl shRNA animals exhibited 
wide heterogeneity in tumor size. Next, we determined the number of metastases on the lung 
surface visualised after X-Gal staining. Fig. 3C shows representative images of X-Gal stained 
lungs of animals with EV, Ctrl shRNA and shCD44 bearing tumors. The numbers of 
metastatic nodules were increased 2-fold and 2.4-fold compared to that of in the EV group 
(p<0.05) and the Ctrl shRNA group (p<0.05), respectively (Fig. 3D).  
CD44 suppression is maintained in vivo on tumor cells containing hyaluronan-
rich extracellular matrices 
After these unexpected findings regarding the primary tumor growth and metastases 
formation that are in conflict with the in vitro data, we asked whether CD44 suppression is 
still stable in vivo. For this reason, we performed immunohistochemistry with Hermes3 
antibody on tumor sections from the three experimental groups. Expression of CD44 was high 
in both the EV and Ctrl shRNA tumors (Fig. 4A, B). On the other hand, we found almost no 
CD44 protein expression in tumors formed in mice orthotopically injected with 143-B cells 
transduced with a specific shRNA against CD44 (Fig. 4C). The pulmonary metastases had the 
same CD44 expression pattern as the primary tumors (Fig. 4G-I). 
The relevance of cell-cell and cell-matrix adhesion and their involvement in each 
subsequent phase of the metastatic journey has been well established and adhesion is 
considered as the fundamental molecular effector mechanism upon which a metastatic cell 
relies [25].  We propose that the detachment of OS cancer cells from the primary tumor mass 
is supported by loss of intercellular and cell-matrix contacts in 143-B shCD44 cells through 
down-regulation of CD44. Therefore, we used immunostaining with recombinant CD44-Fc 
chimera with the aim to detect hyaluronan in primary tumors that originate from manipulated 
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143-B cells. Irrespective of CD44 presence or absence on tumor cells, hyaluronan was found 
to be abundantly expressed in the extracellular matrices of these cells (Fig. 4 D-F). Decreased 
adhesion of 143-B shCD44 cells to hyaluronan-rich matrices may facilitate their spread 
beyond the primary tumor site, finally leading to elevated metastatic ability. Indeed, Ki67 
staining of proliferating tumor cells showed a specific structure of primary tumors and lung 
metastases in mice bearing tumors depleted of CD44. As opposed to EV and Ctrl shRNA 
carrying 143-B cells that are compactly organized and in close cell contact with each other 
(Fig. 5A, B, D, E), 143-B shCD44 cells show a low-adhesive phenotype with wide inter-
cellular spaces (Fig. 5C, F). This lack of cell-cell junctions might simplify cell motility and 
dissemination. 
Merlin expression in vivo is suppressed upon CD44 silencing 
It has been reported that CD44 interacts with merlin, a tumor and metastasis suppressor. 
When exposed to hyaluronan CD44 binds through its cytoplasmatic tail to merlin that is 
subsequently activated to confer growth arrest by contact inhibition [26]. Therefore, we 
sought to explore merlin protein levels in manipulated 143-B cells. In vitro, all three cell lines 
expressed equal protein amounts of merlin (not shown). In contrast, merlin expression was 
diminished in primary tumors, as well as in pulmonary metastases in mice bearing shCD44 
xenografts when compared to tumor tissue in EV and Ctrl shRNA xenografts (Fig. 5 G-L). 
The lack of merlin in vivo might be correlated with the increase in tumor volume and 
metastatic capacity of 143-B shCD44 cells.   
Discussion 
Only a few studies addressed so far the association of CD44 expression with OS 
progression and metastasis, however obtained results are controversial. Either no correlation 
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between CD44 gene or protein expression with overall survival of OS patients was observed 
[27], or OS patients with high CD44 gene expression were found to be more metastases prone 
in another cohort [28]. Moreover, expression of distinctive CD44 isoforms were found to be 
correlated with unfavorable prognosis [16,17].  
Here, we aimed at determining the role of CD44 in the human 143-B OS cell line with high 
metastatic activity, which have high endogeneous CD44 expression. Therefore, we down-
regulated CD44 expression in 143-B cells and studied its impact both in in vitro assays and in 
an in vivo xenograft mouse OS model. In vitro, stable shRNA-mediated CD44 knock-down 
significantly suppressed cell migration and growth in soft agar, implying that CD44 may 
contribute to the increased metastatic properties of 143-B cells.  However, upon intratibial 
injection into SCID mice, 143-B cells with reduced CD44 expression even enhanced the 
malignant phenotype when compared to control cells. Mice bearing shCD44 xenografts 
developed larger primary tumors and had significantly increased number of pulmonary 
metastases when compared to those in control animals. In contrast to our in vitro data, 
experiments in vivo using the orthotopic xenograft mouse model identify CD44 as a 
metastasis suppressor gene in 143-B cells.  
A plausible explanation for the enhanced metastatic activity in cells depleted of CD44 is 
their decreased adhesion to HA-rich extracellular matrices within primary tumors, consistent 
with the reduced adhesion to HA we observed in vitro. Furthermore, histology of tumor tissue 
revealed a low adhesive structure of 143-B shCD44 cells with wide intercellular gaps, as 
opposed to control transduced cells. The changes in adhesive properties of shCD44 cells may 
also have facilitated their mobility and enabled expansion and dissemination beyond the 
primary tumor site, ultimately leading to elevated metastatic potential. Study performed by 
Lopez et al. is in good agreement with our concept, in which they report that CD44 loss has a 
metastasis-promoting effect in a mouse model of spontaneously metastasizing breast cancer 
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[29]. Moreover, the authors show that CD44/HA interactions inhibit invasion in a three-
dimensional in vitro invasion assay, suggesting that CD44 engagement with HA is protective 
against metastasis. Another explanation for the elevated malignant phenotype in 143-B cells 
with silenced CD44 is the observed loss of merlin protein expression in vivo in these cells. 
Merlin is encoded by neurofibromatosis type 2 (NF2) gene and mutations and deletions of 
merlin underlie NF2 familial cancer syndrome, characterized by development of 
schwannomas, meningiomas and ependymomas [30]. As mutations of NF2 were also detected 
in other cancer types, it is considered as a tumor suppressor gene in a wide variety of tumor 
cells. Merlin is a multifunctional protein that regulates cell shape, proliferation, survival, 
motility and invasion. Interestingly, mice heterozygous for a mutation at the NF2 locus 
(Nf2+/-) are cancer prone, and develop a wide spectrum of tumors, most frequently OS, that 
display strikingly high metastatic proclivity, unlike the benign tumors in human patients with 
NF2 syndrome [31]. This study provided experimental support for the association of NF2 loss 
and elevated metastatic potential. Conversely to the observations in mice, in human OS 
patient samples NF2 mutations could not be found, whereas merlin protein could be detected, 
implicating the apparent differences between the mouse and human OS tumorigenesis [32]. 
Nevertheless, as merlin functions as a tumor and metastasis suppressor, accelerated tumor 
growth and enhanced ability to form metastases seen in the intratibial OS mouse model 
presented here may be the conse uence of  loss of merlin’s expression in 14 -B shCD44 cells. 
A recent report showed that the loss of merlin protein observed in breast cancer tissues is a 
result of proteosomal degradation induced by osteopontin initiated Akt-mediated 
phosphorylation of merlin [33]. Mechanisms underlying merlin loss in OS cells need yet to be 
elucidated.  Additionally, merlin has been reported to reverse the Ras-induced malignant 
phenotype [34]. Given the fact that 143-B cells were generated through Ki-Ras transformation 
[35], we suggest that Ras-driven metastatic behavior is even more pronounced upon loss of 
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merlin protein expression in vivo. Therefore, we cannot exclude the possibility of a cell-type 
specific effect of CD44 down-regulation on tumor and metastasis formation. However, CD44 
may act as a metastasis suppressor by regulating merlin expression or function in a subset of 
OS where Ras signaling is involved.  
In conclusion, the findings of our study implicate CD44 as a negative regulator of 
metastasis in 143-B OS cells. The apparent discrepancy between in vitro and in vivo outcomes 
of CD44 knock-down on tumorigenic and metastatic properties of 143-B cells highlights the 
essential impact of tumor surroundings on OS progression. CD44 functions as a metastasis 
suppressor gene in this particular experimental OS, however future studies focusing on the 
role of different CD44 isoforms in additional established OS cell lines or in primary cells, as 
well as investigating CD44 expression in large cohorts of human tumor tissue samples, will 
contribute to the delineation of its’ role in OS.  
Acknowledgments  
We thank Prof. Ivan Stamenkovic (Department of Experimental Pathology, University of 
Lausanne) for providing CD44 expression constructs and helpful discussion and Dr. S. 
Jalkanen (Turku, finland) for providing Hermes3 antibody. We thank Dr. med. Vet. Monika 
Hilbe (Institute of Veterinary Pathology, Zurich) for the help in immunohistochemistry 
stainings of hyaluronan and we thank Josefine Bertz and Christopher Bühler for excellent 
technical assistance. 
This work was supported in part by the Zurcher Krebsliga (Zurich, Switzerland), the Swiss 
National Science Foundation (SNF Grant Nr.31003A-120403), the University of Zurich, the 
Schweizerischer Verein Balgrist (Zurich, Switzerland), the Walter L. & Johanna Wolf 
Foundation (Zurich, Switzerland), and the Lydia Hochstrasser Stiftung (Zurich, Switzerland). 
Gvozdenovic et al 17 
    
  
Author’s Contributions 
Designed the study: AG, RM, BF, WB; Conducted experiments: AG; Animal work: AG, 
MJEA, CC, PB; Provided material: KH; Analyzed data: AG; Wrote the manuscript: AG, RM, 
WB, BF.  
References     
1. Picci P (2007) Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2: 6. 
2. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, et al. (1986) The Effect of Adjuvant 
Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity. 
New England Journal of Medicine 314: 1600-1606. 
3. Marina N, Gebhardt M, Teot L, Gorlick R (2004) Biology and Therapeutic Advances for Pediatric 
Osteosarcoma. Oncologist 9: 422-441. 
4. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y (2002) CD44 in cancer. Crit Rev Clin Lab Sci 39: 
527-579. 
5. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (1990) CD44 is the principal cell surface 
receptor for hyaluronate. Cell 61: 1303-1313. 
6. Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. 
Nat Rev Mol Cell Biol 4: 33-45. 
7. Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth 
regulation. J Mol Histol 35: 211-231. 
8. Heider K-H, Dämmrich J, Skroch-Angel P, Müller-Hermelink H-K, Vollmers HP, et al. (1993) 
Differential Expression of CD44 Splice Variants in Intestinal- and Diffuse-Type Human Gastric 
Carcinomas and Normal Gastric Mucosa. Cancer Research 53: 4197-4203. 
9. Rall CJN, Rustgi AK (1995) CD44 Isoform Expression in Primary and Metastatic Pancreatic 
Adenocarcinoma. Cancer Research 55: 1831-1835. 
10. Penno MB, August JT, Baylin SB, Mabry M, Linnoila RI, et al. (1994) Expression of CD44 in Human 
Lung Tumors. Cancer Research 54: 1381-1387. 
11. Lim S, Young A, Paner G, Amin M (2008) Prognostic role of CD44 cell adhesion molecule 
expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 
cases. Virchows Archiv 452: 49-55. 
12. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, et al. (1993) Binding of Ovarian Cancer Cells 
to Peritoneal Mesothelium in Vitro Is Partly Mediated by CD44H. Cancer Research 53: 3830-
3838. 
13. Shtivelman E, Bishop JM (1991) Expression of CD44 is repressed in neuroblastoma cells. pp. 5446-
5453. 
14. Angelo M. De Marzo CBJSJIEGJM (1998) CD44 and CD44v6 downregulation in clinical prostatic 
carcinoma: Relation to Gleason grade and cytoarchitecture. Prostate. pp. 162-168. 
15. Gao AC, Lou W, Dong J-T, Isaacs JT (1997) CD44 Is a Metastasis Suppressor Gene for Prostatic 
Cancer Located on Human Chromosome 11p13. pp. 846-849. 
16. Kim HS, Park YB, Oh JH, Jeong J, Kim CJ, et al. (2002) Expression of CD44 isoforms correlates with 
the metastatic potential of osteosarcoma. Clin Orthop Relat Res: 184-190. 
17. Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, et al. (1999) Expression of CD44 variants in 
osteosarcoma. J Cancer Res Clin Oncol 125: 646-652. 
Gvozdenovic et al 18 
    
  
18. Hosono K, Nishida Y, Knudson W, Knudson CB, Naruse T, et al. (2007) Hyaluronan 
oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro 
and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol 
171: 274-286. 
19. Nishida Y, Knudson W, Knudson CB, Ishiguro N (2005) Antisense inhibition of hyaluronan 
synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. 
Exp Cell Res 307: 194-203. 
20. Tofuku K, Yokouchi M, Murayama T, Minami S, Komiya S (2006) HAS3-related hyaluronan 
enhances biological activities necessary for metastasis of osteosarcoma cells. Int J Oncol 29: 
175-183. 
21. Janiszewska M, De Vito C, Le Bitoux MA, Fusco C, Stamenkovic I (2010) Transportin regulates 
nuclear import of CD44. J Biol Chem 285: 30548-30557. 
22. Arlt MJ, Banke IJ, Walters DK, Puskas GJ, Steinmann P, et al. (2011) LacZ transgene expression in 
the subcutaneous Dunn/LM8 osteosarcoma mouse model allows for the identification of 
micrometastasis. J Orthop Res. 
23. Arlt M, Kopitz C, Pennington C, Watson KLM, Krell H-W, et al. (2002) Increase in Gelatinase-
specificity of Matrix Metalloproteinase Inhibitors Correlates with Antimetastatic Efficacy in a 
T-Cell Lymphoma Model. Cancer Research 62: 5543-5550. 
24. Kruger A, Schirrmacher V, von Hoegen P (1994) Scattered micrometastases visualized at the 
single-cell level: detection and re-isolation of lacZ-labeled metastasized lymphoma cells. Int J 
Cancer 58: 275-284. 
25. Bacac M, Stamenkovic I (2008) Metastatic cancer cell. Annu Rev Pathol 3: 221-247. 
26. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, et al. (2001) The NF2 tumor suppressor gene 
product, merlin, mediates contact inhibition of growth through interactions with CD44. 
Genes Dev 15: 968-980. 
27. Boldrini E, Peres SV, Morini S, de Camargo B (2010) Immunoexpression of Ezrin and CD44 in 
patients with osteosarcoma. J Pediatr Hematol Oncol 32: e213-217. 
28. Xu-Dong S, Zan S, Shui-er Z, Li-na T, Wen-xi Y, et al. (2009) Expression of Ezrin correlates with lung 
metastasis in Chinese patients with osteosarcoma. Clin Invest Med 32: E180-188. 
29. Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J, et al. (2005) CD44 attenuates 
metastatic invasion during breast cancer progression. Cancer Res 65: 6755-6763. 
30. Stamenkovic I, Yu Q (2010) Merlin, a "magic" linker between extracellular cues and intracellular 
signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 
11: 471-484. 
31. McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, et al. (1998) Mice heterozygous for a 
mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. 
Genes Dev 12: 1121-1133. 
32. Stemmer-Rachamimov AO, Nielsen GP, Rosenberg AE, Louis DN, Jones D, et al. (1998) The NF2 
gene and merlin protein in human osteosarcomas. Neurogenetics 2: 73-74. 
33. Morrow KA, Das S, Metge BJ, Ye K, Mulekar MS, et al. (2011) Loss of tumor suppressor Merlin in 
advanced breast cancer is due to post-translational regulation. J Biol Chem 286: 40376-
40385. 
34. Tikoo A, Varga M, Ramesh V, Gusella J, Maruta H (1994) An anti-Ras function of 
neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 269: 23387-23390. 
35. Rhim JS, Cho HY, Huebner RJ (1975) Non-producer human cells induced by murine sarcoma virus. 
Int J Cancer 15: 23-29. 
 
 
Gvozdenovic et al 19 
    
  
Figure Legends 
Figure 1. CD44 down-regulation of CD44 expression by shCD44 in 143-B cells. (A) Western 
blot analysis showed nearly complete abolishment of total CD44 expression in 143-B cells 
infected with the CD44 specific shRNA (shCD44) compared to the cells infected with the 
control shRNA (Ctrl shRNA) and the empty vector (EV). GAPDH was used as a loading 
control. (B) CD44 surface expression, assessed by immunocytochemistry in non-
permeabilized cells revealed reduced CD44 membrane expression in 143-B shCD44 cells 
when compared to that of 143-B EV and 143-B Ctrl shRNA. 
Figure 2. In-vitro functional assays. CD44 silencing decreases adhesion to HA (A, n=3), 
migration in the trans-filter migration assay (B, n=6), and the cells’ capacity for anchorage-
independent growth in soft agar (D, n=4), but proliferation of adherent cells is not affected (C, 
n=3). Values represent the mean ± SEM; *, p<0.05. 
Figure 3. Primary tumor growth and lung metastases formation after intratibial injection of 
transduced 143-B cells into SCID mice. (A) X-ray monitoring of tumor development showed 
similar extent of osteolytic lesions in all animal groups. (B) Primary tumor volume was 
determined every 7 days. Mice injected with cells transduced with the specific shRNA against 
CD44 (shCD44, n=9) developed larger tumors in comparison to the EV (n=9) and Ctrl 
shRNA (n=6) experimental groups. (B) Representative photos of the lungs with the blue X-
gal stained metastases of mice bearing EV, shCD44 and Ctrl shRNA xenografts. (D) CD44 
knock-down promotes metastases in the lungs. Values are expressed as mean ± SEM; *, 
p<0.05. 
Figure 4. CD44 and HA immunohistochemical analyses of primary tumors and pulmonary 
metastases. CD44 levels are remarkably diminished in primary tumor (PT) and pulmonary 
metastases (PM) sections of mice bearing tumors with specific shRNA against CD44 (C, I), 
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compared to EV (A,G) and Ctrl shRNA bearing animals (B,H). HA is abundantly expressed 
in primary tumors (E) in all animal groups. Hermes3 antibody and recombinant CD44-Fc 
chimera were used to detect CD44 and HA on tissue sections, respectively. Nuclei were 
counterstained with hematoxylin. Bar, 100 µm. 
Figure 5. Ki67 and merlin immunohistochemical analyses of primary tumors and pulmonary 
metastases. Tissue sections of primary tumors (PT) and pulmonary metastases (PM) stained 
with polyclonal anti-Ki67 antibody revealed dense organisation of closely attached  
proliferating cells in EV (A,D) and Ctrl shRNA (B,E) xenografts, in contrast to shCD44 
xenografts which displayed a loose structure assembled by low adhesive tumor cells (C,F).  
Primary tumors and pulmonary metastases originating from 143-B lacking CD44 were almost 
devoid of merlin expression (I,L), compared to CD44 positive tumors and metastases of 
control mice (G,H,J,K). Bar, 100 µm. 
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4.3 Additional studies: 
Effects of CD44v6 overexpression on tumorigenic and metastatic 
properties of human SaOS-2 osteosarcoma cells in vitro and in vivo 
4.3.1 Results 
 The first major finding that showed a role for CD44 in metastatic spread was the 
discovery that the CD44 isoform containing the sequence encoded by the v6 exon confers 
metastatic potential to non-metastasizing rat pancreatic carcinoma cells (Günthert et al., 
1991). In the following decades, numerous reports linked CD44v6 expression to poor 
prognosis of patients suffering from various cancer types including colorectal, cervical, 
gastric and breast cancer (Orian-Rousseau, 2010). Interestingly, Kuryu et al. found that 
overexpression of CD44v6 in tumor specimens correlated with a poor prognosis in 
osteosarcoma (OS) patients (Kuryu et al., 1999).  
Therefore, in order to determine the potential effects of CD44v6 expression on the 
tumorigenicity and the metastatic behavior of osteosarcoma cells, we overexpressed by 
retroviral gene transfer a C-terminally V5/His6 tagged CD44v6 isoform in low-metastatic 
SaOS-2/LacZ cells (SaOS-2 CD44v6 cells), with no endogenous CD44v6. Control cells 
SaOS-2/LacZ were transduced with the pQCIXH empty vector (EV) to reveal SaOS-2 EV. 
Stable overexpression of CD44v6 protein was confirmed by Western blot analysis of cell 
extracts and immunocytochemistry (Figure Z1). The transductants were further characterized 
in vitro in functional assays as well as in vivo for their ability to form primary tumors and 
pulmonary metastases. 
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Figure Z1. CD44v6 overexpression in low-metastatic human SaOS-2 OS cells. (A) Overexpression 
of CD44v6-V5/His6 achieved through retroviral gene transfer was confirmed by Western blot analysis using 
both V5 and CD44v6 antibodies. GAPDH was used as a loading control. (B) Immunocytochemistry performed 
with anti-V5 antibody revealed CD44v6 overexpression in approximately 80% of cells. 
 
CD44v6 overexpression does not alter the adhesion to immobilized 
hyaluronan, but it increases the migration capacity and inhibits proliferation of 
SaOS-2 cells in vitro 
First, we tested the stable transductants for short term adhesion to hyaluronan (HA), 
the major ligand for CD44. SaOS-2 CD44v6 cell showed a2.3- fold increased adhesion 
compared to the EV control cells (p < 0.25; Fig Z2A). We further examined the potential 
effect of CD44v6 overexpression on the migratory properties of SaOS-2 cells in a transwell 
migration assay. CD44v6 overexpression resulted in a significant 8-fold increase in the 
migration rates when compared to EV cells (p < 0.05; Fig Z2B). Next, we explored whether 
CD44v6 overexpression has any impact on the proliferation of SaOS-2 cells in vitro. 
Proliferation of SaOS-2 CD44v6 cells was significantly (p < 0.05) decreased when compared 
to that of SaOS-2 EV cells, and the calculated doubling times were 38.2 ± 1.6h for SaOS-2 
EV and 43.7 ± 1.6h for SaOS-2 CD44v6 cells (Fig Z2C). 
 
93 
 
 
Figure Z2. Overexpression of CD44v6 in SaOS-2 cells promotes migration and inhibits 
proliferation, but does not alter adhesion to HA. (A) Short-term (30 min) adhesion of SaOS-2 EV and SaOS-2 
CD44v6 cells to immobilized HA. Migration rates assessed in a transwell migration assay (B)  and (C) 
proliferation of EV and CD44v6 transduced SaOS-2 cells. Values are expressed as means ± SEM of at least three 
independent experiments; *, p < 0.05. 
 
CD44v6 overexpression in osteoblastic SaOS-  cells does not have a 
significant impact on intratibial primary tumor growth and the number of 
pulmonary macrometastases, but significantly decreases the number of 
micrometastases 
After the characterization of CD44v6 overexpressing SaOS-  cells in vitro, we 
investigated the tumorigenic and metastatic properties of SaOS-  CD44v6 cells in vivo. 5 x 
105 of SaOS-  EV or SaOS-  CD44v6 cells were intratibially injected into 
immunocompromised SCID CB17 mice. Primary tumor growth and resulting osteoblastic 
lesions were monitored by X-ray (Figure Z B). In the 1 th week after tumor cell injection, 
mice became moribund and were conse uently sacrificed. Osteoblastic lesions in the tumor-
injected legs were comparable in the two groups of animals. Tumors derived from SaOS-  
CD44v6 cells tended to grow more slowly than those developing from SaOS-  EV cells (p < 
0.08; Fig Z4A). Mean calculated final volumes of SaOS-2 CD44v6 and SaOS-2 EV 
xenografts were 72 ± 19 mm
3
 and 143 ± 28 mm
3
, respectively. 
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 Figure Z3. X-ray monitoring of primary tumor development upon intratibial injection of SaOS-2 
EV and SaOS-2 CD44v6 cells into SCID mice. (A) Representative X-ray control image confirming the correct 
position of the Hamilton syringe during intratibial tumor cell injection (TCI). (B) Representative X-ray images 
of tumor-bearing legs taken on indicated day after injection of SaOS-2 EV cells (11 mice) or of SaOS-2 CD44v6 
cells (7 mice). (C) Representative X-ray image of  a non-injected control leg. 
 
 As described previously, the cells used were transduced with a LacZ gene which 
allowed ex vivo X-Gal staining of whole lung mounts and thereby tracking of tumor cells in 
mouse tissue and quantification of pulmonary metastatic nodules. Mean number of lung 
macrometastases did not significantly differ between the mice bearing SaOS-2 CD44v6 cell-
derived xenografts and mice with SaOS-2 EV cell-derived tumors (p > 0.5; Figure Z4B). 
Mice with CD44v6 overexpressing tumors, on the other hand, showed a 2.2-fold higher mean 
number of lung micrometastases than mice with SaOS-2 EV cell derived tumors (p < 0.05; 
Figure Z4C). 
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Figure Z4. Primary tumor growth and formation of pulmonary metastases upon intratibial 
injection of SaOS-2 EV and SaOS-2 CD44v6 cells into SCID mice. (A) Mean (± SEM) primary tumor volume 
of mice bearing SaOS-2 EV cell-derived (n=11) or SaOS-2 CD44v6 cell-derived (n=7) tumors 12 weeks after 
tumor cell injection. Quantification of pulmonary macrometastases (B) and micrometastases (C) on whole lung 
mounts prepared after sacrifice of the mice in week 12 after tumor cells injection. Values are presented as mean 
± SEM; *, p < 0.05 
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4.3.2 Materials and Methods 
Generation of CD44v6 expression construct and retroviral infection 
A cDNA fragment encoding the v6 exon of CD44 was amplified by RT/PCR from 
total RNA isolated from human 143-B cells (ATCC; CRL-8303) using the following primers: 
 5’-ACTATTGTTAACCGTGATGGCACCC- ’  
 5’-ATTCTCGAGTCACCCCAATCTTCATGT- ’. 
The PCR product was cloned into the pGEM
®
-T Easy Vector (Promega, Madison, WI) 
and then inserted at the proper position of the nucleotide sequence encoding CD44s with C-
terminal V5 and His6 tags, which had earlier been cloned into the retroviral expression vector 
pQCIXH. This gave rise to pQCIXH CD44v6-V5/His6. The sequence was verified by 
sequencing of both strands. The retroviral particles containing pQCIXH EV (empty vector) 
and pQCIXH CD44v6-V5/His were generated in HEK 293T (ATCC; CRL-11268) cells and 
subsequently used to infect SaOS-2/LacZ cells as described (Arlt et al., 2011). Selection with 
hygromycin (400 µg/ml) revealed SaOS-2 EV and SaOS CD44v6 stable cell lines. Apecific 
anti-CD44v6 antibody used for detection of CD44v6 in WB at the dilution of 1:1000 was 
purchased from Bender MedSystems. 
 
Western blot, immunocytochemistry, adhesion assay, transwell migration assay, 
proliferation assay and the animal experiments were all performed as described in detail in the 
Material and Methods section in Manusript 1. 
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4.3.3 Discussion 
 Only two immunohistochemichal studies revealed correlation of CD44 variant 
expression in OS tumor samples and poor prognosis for the patients, however one study 
claimed CD44v5 to be important, whereas the other found CD44v6 to be relevant for patients 
outcome (Kim et al., 2002; Kuryu et al., 1999). Using primers that span the variant exons, we 
performed expression analysis of CD44 isoform expressed in 8 established human OS cell 
lines and found CD44 standard isoform to be predominantly expressed. CD44v6 isoform 
expression was observed as a minor fraction in 5 out of 8 cell lines (data not shown). 
Therefore, we aimed at investigating the in vitro and in vivo effects of CD44v6 
overexpression in SaOS-2 on their tumorigenic and metastatic behavior. The SaOS-2 cells 
were chosen for manipulation experiments because they are negative for CD44v6 protein 
expression, and have almost undetectable CD44s expression. Stable CD44v6 overexpressing 
transductants showed only a tendency of higher adhesion to HA in vitro when compared to 
that of control cells. As described in the thesis introduction, the HA-binding site is located in 
the standard part, but the insertion of variant exons and glycosylation state that is cell-type 
specific can significantly modify the ability to bind HA. Similar to our results, a CD44 variant 
containing v6 exon encoded sequence when overexpressed in human Burkitt lymphoma 
Namalwa cells only slightly increased adhesion to HA (Bartolazzi et al., 1995). On the 
contrary to the adhesion, CD44v6 overexpression notably promoted the migration of SaOS-2 
cells in vitro. Although the mechanism of CD44v6 regulated migration in OS needs to be 
clarified, the likely explanation would be analogous to some human carcinoma cell lines 
where the CD44v6 isoform forms a complex with c-Met/HGF that subsequently promotes cell 
motility (Orian-Rousseau et al., 2002). CD44v6 overexpression decreased the in vitro 
proliferation rate of SaOS-2 cells. To summarize the in vitro effects of CD44v6 
overexpression, it strongly enhanced migration, an important indicator of metastatic activity, 
however, it reduced the growth rate, an indicator of tumorigenicity. With the use of the 
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xenograft OS mouse model, we found that CD44v6 overexpressing SaOS-2 cells showed only 
a tendency of forming smaller tumors compared to control cells upon intratibial injection and 
this finding is in line with our in vitro observations of slower tumor cell growth. On the other 
hand, outgrowth of pulmonary metastases did not significantly differ in mice of the 
experimental and control groups, which was reflected in the similar number of formed 
macrometastases. However, the number of micrometastases in the lungs of mice bearing 
SaOS-2 CD44v6 cell-derived tumors was significantly reduced compared to mice with SaOS-
2 EV-derived tumors. As the number of SaOS-2 CD44v6-originating macrometastases is 
comparable and the number of micrometastases is decreased when compared to that formed 
by SaOS-2 EV cells, we suspect that CD44v6-overexpressing cells disseminate within the 
lung tissue, eventually giving rise to nodules larger than 0.1mm in diameter. Additional 
experiments are required to determine which lung tissue factors interplay with CD44v6-
overexpressing tumor cells leading to their elevated dissemination and outgrowth in the lungs. 
 In conclusion, CD44v6, distinct from CD44s, does not appear to play a relevant role in 
regulating OS progression and metastasis in this particular orthotopic xenograft OS mouse 
model. The findings presented here underline the importance of CD44s, but not variant CD44 
isoforms, for OS progression, as discussed in Manuscript 1.  
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5 Conclusion and Outlook 
 Pulmonary metastases are the major cause of death in OS patients and despite the 
clinical advances and the use of multi-modality treatment patients suffering from metastatic 
disease continue to have a very poor prognosis. The development of successful disease 
management strategies that eradicate metastases requires detailed understanding of molecular 
mechanisms and knowledge on key regulators of increased metastatic spread and/or 
chemoresistance. Acquiring profound knowledge of fundamental biology of OS and 
identification of novel OS molecular markers will aid the design of targeted effective 
treatment of this devastating disease. 
 In the thesis presented here, the prognostic value of CD44 expression for OS patients’ 
outcome and the biological relevance of CD44/HA interactions for OS malignancy in 
orthotopic xenograft OS mouse models were investigated.  
 Our tissue microarray analysis of OS tumor specimens identified CD44 as an 
additional indicator for poor patient’s outcome together with the lack of response to 
chemotherapy and the presence of metastases, that are up to date the most powerful and 
reliable predictors for a poor prognosis for OS patients. We consider CD44 as a molecular 
marker that can be used for stratification of patients into different-risk groups. This sets a 
framework for personalized treatment, which allows tailored therapy for individual patients 
according to the molecular profile of their tumors. The ultimate goal is to enhance treatment 
efficacy while minimizing the adverse side effects of anticancer drugs, which is especially 
important for the treatment of rapidly growing pediatric patients. In our cohort of patients that 
poorly respond to neoadjuvant chemotherapy and of patients with metastases, those with 
CD44 expression by the tumor represent a high-risk group and may therefore be considered as 
candidates for novel therapeutic strategies. 
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 At the same time, our results in experimental models of OS highlight CD44/HA 
interaction as a promising target for therapeutic intervention in OS. Making use of a xenograft 
orthotopic OS mouse model, that closely reproduces the human disease, we demonstrate for 
the first time that CD44s, but not CD44v6, has a tumor- and metastatis-promoting activity 
upon overexpression in a human non-transformed osteoblastic SaOS-2 cell line. The 
malignancy enhancing effect of CD44s was HA-dependent. In addition to enhancing the 
tumorigenic and metastatic behavior of SaOS-2 cells, CD44 was found to be associated with 
chemoresistance to cisplatin in vitro.  Future studies should be focused on addressing the 
possible signaling pathways involved and on exploring the potential CD44 linked 
chemoresistance in vivo. 
 Conversely, when we explored the contribution of CD44 to the OS malignant 
phenotype in another xenograft model of OS, we found that CD44 acts as a metastasis 
suppressor in this particular experimental setup. Namely, CD44 silencing in the highly 
metastatic human 143-B cell line resulted in increased metastatic potential probably due to 
reduced adhesion at the primary tumor site and loss of expression of the metastasis suppressor 
merlin in vivo. 143-B cell line is a Ki-Ras transformed cell line, and, although at this point we 
cannot exclude the possibility of a cell-type specific effect of CD44 down-regulation, it is 
reasonable to suggest that CD44 may act as a negative regulator of metastasis in a subset of 
OS where Ras signaling is involved.  
  Various approaches have been described in the literature to interfere with CD44/HA 
interactions in vitro and in vivo in different murine tumor models, including a few studies in 
experimental OS.  Along these lines, exchange of endogenous multivalent HA with small 
monovalent HA oligomers (Hosono et al., 2007), the use of antisense inhibition of HA 
synthase 2 (Nishida et al., 2005) or treatment with an inhibitor of HA synthesis 4-
methylumbelliferon (Arai et al., 2011) have been reported. However, a functional inhibition 
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of CD44 by displacement of endogenous HA with the use of soluble HA-binding CD44 
proteins, that we are investigating in addition to our CD44 silencing experiments, as well as 
inhibition of CD44/HA interaction with blocking antibodies (e.g. Hermes1), may in the future 
clarify the relevance of CD44 in different mouse models of OS. 
 Taken together, we can conclude that CD44 may have a dual role in regulating OS 
progression and metastasis depending on the cellular background or the experimental models 
used, as shown in breast cancer (Louderbough and Schroeder, 2011). However, in the context 
of osteoblastic OS, the most common type of OS, our study demonstrated that CD44s 
promotes OS growth and dissemination and its interaction with HA may serve as a potential 
therapeutic target. In addition to targeting CD44/HA interactions directly, these interactions 
can also be utilized for the delivery of anticancer drugs to CD44 expressing tumor cells. For 
example, drug-loaded liposomes or nanoparticles decorated with HA or anti-CD44 antibody 
showed efficacy in animal tumor models (Platt and Szoka, 2008). Initial trials with anti-
CD44v6 antibodies coupled to radioisotopes or cytotoxic drugs in head and neck squamous 
cell carcinoma and breast cancer patients showed some clinical success, although 
complications with various toxicities occurred (Orian-Rousseau, 2010). As CD44s is an 
abundantly expressed molecule that plays central roles in numerous physiological processes, 
there is concern regarding selective targeting of cancer cells. Nevertheless, it appears that 
malignant tumors have higher sensitivity to disruption of CD44/HA interaction than normal 
physiological processes (Toole, 2009). In order to avoid adverse side effects, the most 
promising strategy would be to use bispecific antibodies, targeting two different antigens on a 
cancer cell, as it was shown for CD44 and a leukemia idiotype (Avin et al., 2004).   
  Because of the high degree of heterogeneity of OS tumor cells, future 
investigations in additional OS cell lines, ideally primary human OS cells, are likely to give 
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informative results finally leading to detailed delineation of the relevance of CD44/HA 
interaction for different subtypes of OS.  
 In conclusion, results presented in this thesis clearly demonstrate that, at least in 
experimental osteoblastic OS, CD44s/HA interaction plays a malignancy promoting role and 
that these molecules are promising targets for successful treatment of this highly aggressive 
cancer type.        
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